

การโคลนนิ่งและการแสดงออกของฟอสโฟไลเปสจากพิษงูแมวเซา



นางสาว สวัสดิ์รักษ์ พงศ์ชนานันท์

วิทยานิพนธ์นี้เป็นส่วนหนึ่งของการศึกษาตามหลักสูตรปริญญาวิทยาศาสตรมหาบัณฑิต

สาขาวิชาวิทยาศาสตร์การแพทย์

คณะแพทยศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

ปีการศึกษา 2546

ISBN 974-17-3525-1

ลิขสิทธิ์ของจุฬาลงกรณ์มหาวิทยาลัย

**CLONING AND EXPRESSION OF PHOSPHOLIPASE A<sub>2</sub> FROM RUSSELL'S VIPER  
VENOM (*Daboia russellii siamensis*)**

**Miss Sawatdirak Phongtananant**

**A Thesis Submitted in Partial Fulfillment of the Requirements  
for the Degree of Master of Science in Medical Science**

**Faculty of Medicine  
Chulalongkorn University**

**Academic Year 2003**

**ISBN 974-17-3525-1**



สวัสดิรักษ์ พงศ์ธนนันท์ : การโคลนนิ่งและการแสดงออกของฟอสโฟไลเปสเอจากพิษงู  
 แมวเซา (CLONING AND EXPRESSION OF PHOSPHOLIPASE A<sub>2</sub> FROM RUSSELL'S  
 VIPER VENOM (*Daboia russellii siamensis*)) อ. ที่ปรึกษา : รศ.นพ. อิศรางค์ นุชประยูร. 106  
 หน้า. ISBN 974-17-3525-1.

ฟอสโฟไลเปสเอในพิษงูเป็น โปรตีนที่มีขนาดเล็กประมาณ 13-15 กิโลดาลตัน มีบทบาทเกี่ยวกับ  
 ความเป็นพิษหลายด้าน เช่น เป็นสารด้านการแข็งตัวของเลือด, ทำลายเม็ดเลือด, เป็นตัวชักนำให้เกิด  
 การบวม, ยับยั้งการรวมตัวของเกร็ดเลือด, ทำลายระบบประสาทและกล้ามเนื้อ เป็นต้น เป็นที่ทราบกันดีว่า  
 ในพิษงูแมวเซามีฟอสโฟไลเปสเอหลายแบบซึ่งพบแตกต่างกันในแต่ละหน่วยย่อยของสปีชีส์ ในการ  
 ศึกษานี้มีวัตถุประสงค์เพื่อตรวจหาว่างูแมวเซาของไทยมีฟอสโฟไลเปสเอที่แบบโดยใช้วิธีตรวจหาจาก  
 ห้องสมุดซีดีเอ็นเอ (cDNA library) ของต่อมพิษงูแมวเซาไทยและค้นหาวิธีผลิตฟอสโฟไลเปสเอด้วยวิธี  
 ทางพันธุวิศวกรรมและศึกษาโครงสร้างของยีนสร้างฟอสโฟไลเปสเอ

ผลการตรวจหาฟอสโฟไลเปสเอจากห้องสมุดซีดีเอ็นเอพบว่ามี 2 แบบ คือ *PlaS1* และ *PlaS2*  
 ในสัดส่วนประมาณ 1:2 มีความเหมือนกันของลำดับซีดีเอ็นเอในแต่ละแบบเท่ากับ 86 เปอร์เซ็นต์ ผลการ  
 เทียบกับฐานข้อมูลพบว่า *PlaS1* และ *PlaS2* เหมือนกับ *RV-4* และ *RV-7* ที่พบในงูแมวเซาได้หวั่นตาม  
 ลำดับ การผลิตฟอสโฟไลเปสเอที่เชื่อมกับฮิสติดีนจากพลาสมิดซึ่งมียีน *PlaS1* และ *PlaS2* โดยใช้  
 แบคทีเรีย *E. coli* ได้โปรตีนขนาด 18 และ 23 กิโลดาลตันตามลำดับ เมื่อทำการละลายและปรับให้อยู่ใน  
 สภาพดั้งเดิม (refolding) ได้เอนไซม์ที่มีประสิทธิภาพในการย่อยฟอสโฟไลปิด 185.67 ไมโครโมลต่อนาที  
 ต่อมิลลิกรัม แต่ได้โปรตีนจำนวนเพียง 2 ไมโครกรัมต่อการเลี้ยงเซลล์หนึ่งลิตร การโคลนดีเอ็นเอ  
 ของฟอสโฟไลเปสเอจากจีโนมพบว่ามียีนสร้างฟอสโฟไลเปสเอ 3 ยีนคือ *gPlaS1*, *gPlaS2* และ *gPlaS3*  
 ซึ่งยีนทั้งสามมีขนาดประมาณ 2.0 กิโลเบส ประกอบด้วย 5 exon และ 4 intron นอกจากนี้ยังพบว่า  
*gPlaS1* และ *gPlaS2* ในช่วงบริเวณ coding และ untranslated เหมือนกับ *PlaS1* และ *PlaS2* ตามลำดับ  
 ส่วน *gPlaS3* เมื่อลองทำนายเป็นกรดอะมิโนพบว่าแตกต่างจากฟอสโฟไลเปสเอของงูแมวเซาที่เคยมีราย  
 งานมา

สาขาวิชา วิทยาศาสตร์การแพทย์

ลายมือชื่อนิติ.....

ปีการศึกษา 2546

ลายมือชื่ออาจารย์ที่ปรึกษา.....

437 52876 30 : MAJOR MEDICAL SCIENCE

KEY WORDS: RUSSELL'S VIPER / *Daboia russellii siamensis* /

PHOSPHOLIPASE A<sub>2</sub> / CLONING / EXPRESSION

SAWATDIRAK PHONGTANANANT : CLONING AND EXPRESSION

OF PHOSPHOLIPASE A<sub>2</sub> FROM RUSSELL'S VIPER VENOM (*Daboia*

*russellii siamensis*). THESIS ADVISOR : ASSOC. PROF. ISSARANG

NUCHPRAYOON. 106 pp. ISBN 974-17-3525-1.

Snake venom phospholipaseA<sub>2</sub> (PLA<sub>2</sub>) enzymes are low molecular weight (13-15 kDa) proteins and exhibit a wide variety of pharmacological effects such as hemolysis, platelet aggregation inhibition, neurotoxicity and myonecrosis. Russell's viper (*Daboia russellii siamensis*, RV) venom contains several isoforms of PLA<sub>2</sub> different from each subspecies. The aim of this study was to search for the PLA<sub>2</sub> isoforms in a Thai *Daboia russellii siamensis* venom gland cDNA library, to develop a method of recombinant expression of PLA<sub>2</sub> by genetic engineering and study PLA<sub>2</sub>s gene structure.

By using plaque-lift hybridization and random selection of cDNA library clone for DNA sequence determination, we found only 2 PLA<sub>2</sub> isoforms in the Thai RV venom gland cDNA library with ratio approximately 1:2. The 2 PLA<sub>2</sub> isoforms, designated *PlaS1* and *PlaS2*, showed 86% nucleotide sequence identity and are identical to Taiwan Russell's viper PLA<sub>2</sub>, *RV-4* and *RV-7*, respectively. The PLA<sub>2</sub> isoforms were recombinantly expressed as a histidine tagged fusion protein in using an *E. coli* and yielded 18 kDa and 23 kDa proteins. Because of low level of expression, only the 18 kDa *PlaS1* was expressed in a large scale, purified by using Immobilized Metal Affinity Chromatography (IMAC) under denaturing condition, solubilized, refolded by dialysis and showed PLA<sub>2</sub> activity of 185.67 μmoles/min/mg. The yield of recombinant protein was about 2.0 μg/Litre of cells culture. We cloned the full-length genes encoding PLA<sub>2</sub> by PCR of genomic DNA from muscle tissue of an RV. We identified 3 genes about 2.0 kb in length, designated *gPlaS1*, *gPlaS2* and *gPlaS3*, including 5 exons and 4 introns in genomic PLA<sub>2</sub> DNA cloning. The coding and untranslated regions of *gPlaS1* and *gPlaS2* are identical to *PlaS1* and *PlaS2* cDNA, respectively. The deduced N-terminal amino acid sequences of *gPlaS3*, however, is different from all previous reported of *D. russellii* PLA<sub>2</sub>s.

Field of study Medical Science

Student's signature.....

Academic year 2003

Advisor's signature.....

## ACKNOWLEDGEMENT

I would like to express my sincere gratitude and profound appreciation to Associate Professor Dr. Issarang Nuchprayoon my advisor for his valuable advice, guidance, helpfulness, understanding and intelligential motivation throughout my study.

My grateful appreciation is extended to Associate Professor Dr. Vilai Anomasiri, Associate Professor Dr. Apiwat Mutirangura and Professor Yong Poovorawan, my thesis committees, for their valuable discussion and suggestions.

I feel profoundly indebted to Mr. Preecha Leangaramkul, Mr. Wichai Pornthanakasem and Ms. Patrawadee Pitakpolrat for their helpful, valuable suggestion and encouragement.

I am also really thankful to Mr. Arkhom Saingam, members in the Snake Venom Unit, Filariasis Unit and my friends for their encouragement, sincerity and friendship.

Finally, I will not forget to give special thanks to my parents and every members in my family for their kindness, understanding and cheerfulness.

สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

# CONTENTS

	Page
ABSTRACT (THAI).....	iv
ABSTRACT (ENGLISH).....	v
ACKNOWLEDGEMENT.....	vi
TABLE OF CONTENTS.....	vii
LIST OF TABLES.....	x
LIST OF FIGURES.....	xi
LIST OF ABBREVIATIONS.....	xiv
CHAPTER	
I INTRODUCTION	
- Background and Rationale.....	1
- Research Questions.....	10
- Objective of the Study.....	10
- Hypothesis.....	11
- Key Words .....	11
- Conceptual Framework .....	12
- Expected Benefits and Applications.....	13
II LITERATURE REVIEW.....	14
III MATERIALS AND METHODS	
1. Materials	
- Screening of <i>PLA</i> <sub>2</sub> Clones from ZAP Express cDNA Library.....	21
- <i>PLA</i> <sub>2</sub> Expression.....	23

<b>CHAPTER</b>	<b>Page</b>
- Cloning of Genomic <i>PLA<sub>2</sub></i> DNA (Isolation of Full-length <i>PLA<sub>2</sub></i> ) .....	27
- Chemicals.....	27
- Scope of Work.....	28
2. Methods	
- Screening of <i>PLA<sub>2</sub></i> Clones from ZAP Express cDNA Library.....	29
- <i>PLA<sub>2</sub></i> Expression.....	35
- Protein Purification by Using Immobilized Metal Affinity Chromatography (IMAC) .....	38
- Proteins Detection.....	39
- Refolding of Protein by Dialysis.....	43
- Concentration of Protein by Concentrator.....	43
- Quantitative Assay of <i>PLA<sub>2</sub></i> Protein.....	44
- <i>PLA<sub>2</sub></i> Activity Test.....	44
- Cloning of Genomic <i>PLA<sub>2</sub></i> DNA (Isolation of Full-length <i>PLA<sub>2</sub></i> ) .....	44
 IV RESULTS	
- Screening of <i>PLA<sub>2</sub></i> Clones from cDNA Library.....	46
- <i>PLA<sub>2</sub></i> Expression.....	51
- Protein Purification by Using Immobilized Metal Affinity Chromatography (IMAC) .....	64
- Refolding of Protein by Dialysis.....	67
- Concentration of Protein by Concentrator.....	67
- Quantitative Assay of Recombinant PlaS1 Protein .....	69
- <i>PLA<sub>2</sub></i> Activity Test.....	71
- Cloning of Genomic <i>PLA<sub>2</sub></i> DNA (Isolation of Full-length <i>PLA<sub>2</sub></i> ) .....	73


<b>CHAPTER</b>	<b>Page</b>
V CONCLUSION AND DISCUSSION.....	88
REFERENCES.....	95
APPENDIX.....	101
BIOGRAPHY.....	106



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## LIST OF TABLES

<b>Table</b>	<b>Page</b>
1. Geographical variation in the clinical manifestations of <i>Daboia russellii</i> bite.....	4
2. Phospholipase A <sub>2</sub> groups.....	8
3. Lethal potencies and specific enzymatic activities of viper PLA <sub>2</sub> .....	15
4. The N-terminal amino acid sequences of viper PLA <sub>2</sub> toxin.....	18
5. Restriction enzymes with their recognition sites, recommended buffer and manufacturer.....	23
6. Oligonucleotides and their descriptions.....	24
7. Absorbancy values of PLA <sub>2</sub> activity test.....	71


  
 สถาบันวิทยบริการ  
 จุฬาลงกรณ์มหาวิทยาลัย

## LIST OF FIGURES

Figure	Page
1. Distribution of <i>Daboia russellii</i> subspecies.....	2
2. Morphology of <i>Daboia russellii siamensis</i> .....	3
3. Sites of action of phospholipases.....	5
4. Reaction of catalyzed by PLA <sub>2</sub> .....	6
5. An alignment of deduced mature amino acid sequence PLA <sub>2</sub> s.....	19
6. Map of the ZAP Express vector.....	21
7. Map of the pBK-CMV vector.....	22
8. Map of the pTrcHisA Expression vector.....	24
9. Positive PLA <sub>2</sub> clones in plaque-lift hybridization which shown on X-ray film....	46
10. An ethidium bromide stained agarose gel of double strand phagemid of pBK-CMV digested by <i>EcoR</i> I and <i>Xho</i> I.....	47
11. An alignment of nucleotide sequence of <i>PlaS1</i> and <i>PlaS2</i> .....	49
12. An alignment of deduced amino acid sequence of PlaS1 and PlaS2.....	50
13. An ethidium bromide stained agarose gel showing the 388 bp of PCR products from pBK-CMV phagemid containing PLA <sub>2</sub> -cDNA by using PLAF and PLAR primers.....	52
14. An ethidium bromide stained agarose gel showing ligated-pTrcHis A expression vector with PLA <sub>2</sub> DNA.....	53
15. An ethidium bromide stained agarose gel showing the digestion of ligated-pTrcHisA.....	54
16. PlaS2 and PlaS1 expression inducing with 1 mM IPTG for 3 hours.....	55
17. The other clones of PlaS2 inducing with 1 mM IPTG for 3 hours.....	57
18. Optimization of IPTG which incubation for 3 hours.....	58
19. Optimization of incubation time after adding 1 mM of IPTG .....	59

20. Comparison of PLA <sub>2</sub> expression between DH5 $\alpha$ and TOP10 strain that were induced with 1 mM of IPTG for overnight.....	60
21. Recombinant PlaS1 expression after sonication.....	62
22. Recombinant PlaS2 expression after sonication.....	63
23. Absorbant chromatogram of purified recombinant PlaS1 fractions.....	65
24. Western blot of purified recombinant PlaS1 fractions.....	66
25. A silver stained gel of PlaS1.....	68
26. Standard curve of protein concentration.....	70
27. Absorbance of PLA <sub>2</sub> activity test by spectrophotometric method.....	72
28. An ethidium bromide stained agarose gel showing the PCR products from genomic DNA using 5'FPLA-4F or 5'FPLA-7F and 3'FPLA-R primers.....	74
29. An ethidium bromide stained agarose gel showing the digested pGEM-T plasmids.....	75
30. Homology searching via Internet result of <i>gPlaS1</i> by using BLAST N program at <a href="http://www.ncbi.nlm.nih">www.ncbi.nlm.nih</a> .....	77
31. Homology searching via Internet result of <i>gPlaS2</i> by using BLAST N program at <a href="http://www.ncbi.nlm.nih">www.ncbi.nlm.nih</a> .....	78
32. Homology searching via Internet result of <i>gPlaS3</i> by using BLAST N program at <a href="http://www.ncbi.nlm.nih">www.ncbi.nlm.nih</a> .....	78
33. An alignment between nucleotide sequences of <i>gPlaS1</i> , <i>gPlaS2</i> and <i>gPlaS3</i> .....	79
34. Comparison between cDNA ( <i>PlaS1</i> , <i>PlaS2</i> ) and gDNA ( <i>gPlaS1</i> , <i>gPlaS2</i> and <i>gPlaS3</i> ).....	81
35. An alignment of deduced amino acid sequences of gPlaS1, gPlaS2 and gPlaS3....	84
36. Homology searching via Internet result of deduced amino acid sequence gPlaS3 by using BLAST P program.....	85
37. An alignment of N-terminal amino acid sequence PLA <sub>2</sub> s.....	86

38. Comparison between cDNA and gDNA of PLA<sub>2</sub>s.....87
39. Comparison of amino acid sequences of PLA<sub>2</sub>s.....91




สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## LIST OF ABBREVIATIONS

bp	base pairs
°C	degree Celsius
cm	centimeter
cDNA	complementary deoxyribonucleic acid
DNA	deoxyribonucleic acid
dNTPs	dATP, dTTP, dGTP, dCTP
EDTA	ethylenediamine tetraacetic acid
<i>E. coli</i>	<i>Escherichia coli</i>
g	gram (s)
IPTG	isopropyl-β-D-thiogalactopyranoside
kb	kilobase
LB	Luria-Bertani media
M	molar
MES	2-(N-Morpholino) ethanesulfonic acid
mg	milligram
min	minute
ml	millilitre
mM	millimolar
N	normal
ng	nanogram
nm	nanometer
OD	optical density
pfu	plaque forming unit
pmol	picomole
RNase	ribonuclease

rpm	revolution per minute
SDS	sodium dodecyl sulphate
sec	second
Tris-HCl	tris-(hydroxymethyl)-aminoethane
UV	ultraviolet
$\mu\text{g}$	microgram
$\mu\text{l}$	microlitre
v/v	volume/volume
w/v	weight/volume



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

# CHAPTER I

## INTRODUCTION


### 1. Background and Rationale

Approximately 15 percent of the 3,000 species of snakes found worldwide are considered to be dangerous to humans and classified into three major families: 1) Hydrophidae (sea snakes), 2) Elapidae (cobras, kraits, and coral snakes) and 3) Viperidae (vipers and pit vipers)<sup>1</sup>. Members of family Viperidae are the best-known venomous snakes: true viper e.g. echis species (saw-scaled viper), vipera species (vipers and Russell's viper); pit vipers e.g. crotalus and sistrurus species (rattlesnakes), agkistrodon species (cottonmouth, copperhead)<sup>1</sup>. Out of the 163 species of snake in Thailand, 48 species are member of Elapidae and Viperidae families<sup>2</sup>. These are the most danger out of all venomous snake families. The incidence of bites by venomous snake in Thailand is probably 7,000 per year<sup>2</sup>. Most of snakebites are due to Malayan pit viper, green pit viper, cobras, and Russell's viper, respectively<sup>2</sup>. However, most fatal cases of venomous snake bites in Thai victims, are cobras and Russell's viper, envenoming<sup>2</sup>.


#### 1.1. Russell's Viper

Russell's viper (*Daboia russellii*) is a venomous snake that widely but discontinuously distributed throughout Eastern Asia and Southeast Asia<sup>3</sup>. Taxonomically Russell's viper belongs to class Reptilia, subclass Lepidosauria, order Squamata, suborder Serpentes, superfamily Colubroidea, family Viperidae, subfamily Viperinae, genus *Daboia* (*Vipera*), species *russellii*<sup>4,5</sup>. Russell's viper can be classified to 5 subspecies based on the difference of coloration and markings, *Daboia russellii russellii* (India and Pakistan), *Daboia russellii pulchella* (Sri Lanka), *Daboia russellii*

*siamensis* (Thailand, Myanmar and China), *Daboia russellii formosensis* (Taiwan) and *Daboia russellii limitis* (Indonesia)<sup>3</sup> (**Figure 1**). In Thailand *Daboia russellii siamensis* is found in northern and central area. The snake about 90-120 cm in body length<sup>4</sup>, portly and short shape, triangle-shape head, narrowed neck, short tail, light brown body and heavy brown oval marks<sup>2</sup> (**Figure 2**). They also have large retractable fangs. The average in adult is 16 mm<sup>3</sup>. They are a very muscular snake and can move rapidly and convulsively by lunging movements to attack the aggressor or, more commonly, to attempt escape. The natural prey includes small vertebrates, especially rodents, frogs, lizards, snakes and birds. They are nocturnal and ground dwelling but have occasionally been found swimming and climbing trees<sup>3</sup>.



**Figure 1** Distribution of *Daboia russellii* subspecies<sup>3</sup>.



**Figure 2 Morphology of *Daboia russellii siamensis*<sup>2</sup>.**

### **1.2. Clinical Effect of Russell's Viper Bite**

The Russell's viper venom exhibits a striking geographical variation in the composition and clinical effects of venom even within same subspecies<sup>3</sup> (**Table 1**). Haemostatic abnormalities are described from all countries but the coagulopathy was less marked in Sri Lanka than in Myanmar<sup>6,7</sup>. Pituitary haemorrhage has so far been described only in Myanmar and southern India<sup>3</sup>. Intravascular haemolysis was most marked in Sri Lanka but has been reported from India and Thailand<sup>3</sup>. Neuromyotoxicity is the dominant clinical feature in Sri Lanka and may well occur in India<sup>3</sup>. Chemosis and facial edema, as evidence of increased capillary permeability, have so far been described only in Myanmar where they are common features of severe envenoming<sup>3</sup>. Primary shock and hypotension are most commonly described in Myanmar but have also been mentioned in reports from the other countries<sup>3</sup>.

**Table 1 Geographical variation in the clinical manifestations of *Daboia russellii* bite<sup>3</sup>.**


Symptoms	Sri Lanka	India	Myanmar	Thailand	Taiwan
Coagulopathy	+	++	++	++	?
Renal failure	++	+	++	+	+
Pituitary infarction	-	+	++	-	?
Intravascular haemolysis	++	+	-	+	?
Neuro-myotoxicity	++	+	-	-	?
Generalized capillary permeability	-	-	++	-	?
Primary shock/hypotension	-	+	++	-	?

### 1.3. Proteins in Venom

About 90% of dry weight of snake venom are proteins. Its components include neurotoxins, cytotoxins, cardiotoxins, nerve growth factors, lectins, factor IX/X-binding protein, disintegrins, various enzymes and enzyme inhibitors<sup>8</sup>. Several of proteins are also found in most venomous snakes including hyaluronidase, phospholipase A<sub>2</sub> (PLA<sub>2</sub>), collagenase, nucleotidase, amino acid oxidase, ribonuclease, lactate dehydrogenase, deoxyribonuclease, etc.<sup>3,8,9</sup> The Russell's viper venom can cause the damage of vascular endothelium cause internal hemorrhage<sup>3</sup>. The venom induced disseminated intravascular coagulation (DIC) due to stimulation of coagulation factor X, induced edema, paralysis, wound necrosis and hypotensive effects<sup>3,10</sup>. Deaths which occur between 15 min and 9 days after bite and have been attributed to acute renal failure, vasodilatation, intracranial or massive intra-abdominal haemorrhage, shock caused by increased vascular permeability<sup>3,10</sup>.

### 1.4. Phospholipase A<sub>2</sub>

Phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzymes are separated into several classes, namely A<sub>1</sub>, A<sub>2</sub>, B, C and D, depend on the site of hydrolysis on their substrate<sup>11</sup> (**Figure 3**).




R<sub>1</sub> and R<sub>2</sub> are hydrocarbon chains of fatty acids

X = Head groups

**Figure 3 Sites of action of phospholipases**<sup>11</sup>

PLA<sub>2</sub> enzymes hydrolyze phospholipids at the *sn*-2 position of the glycerol backbone, releasing lysophospholipids and fatty acids<sup>11</sup> (**Figure 4**). PLA<sub>2</sub> enzymes are found as both intracellular and extracellular form<sup>11,12,13</sup>. Mammalian PLA<sub>2</sub> enzymes have important roles in the maintenance of the cellular phospholipid pools

and a variety of physiological and pathological processes<sup>11</sup>. On the other hand, snake venom PLA<sub>2</sub> enzymes are low molecular weight proteins (13-15 kDa) and exhibit a wide diversity of pharmacological effects by interfering in normal cell functions such as anticoagulant<sup>14,15</sup>, haemorrhage<sup>16,17</sup>, edema<sup>18,19,20,21</sup>, platelet aggregation inhibition<sup>14,19</sup>, pre-postsynaptic neurotoxicity<sup>18,19,21,22</sup>, and myonecrosis<sup>18,21</sup>.



**Figure 4** Reaction of catalyzed by PLA<sub>2</sub><sup>11</sup>

Two products of PLA<sub>2</sub> hydrolysis, lysophospholipid and fatty acid, may act as secondary messenger molecules such as arachidonic acid (AA; 5, 8, 11, 14-eicosatetraenoic acid). Generally, these molecules are found at very low level in cells. They also function as the precursor of large family of compound eicosanoids, which includes cyclooxygenase-derived prostaglandins and lipoxygenase-derived leukotrienes. The eicosanoids possess a wide biological activities associate with inflammatory reactions<sup>23</sup>. The lysophospholipid may form platelet-activation factor (PAF), another potent inflammatory mediator<sup>24</sup>.

### 1.5. Classification of Phospholipase A<sub>2</sub>

PLA<sub>2</sub> is a large superfamily of distinct enzymes whose products are important for signal transduction processes, membrane remodeling and general lipid metabolism<sup>13,23</sup>. PLA<sub>2</sub> enzymes can be classified depending on various parameters such as their structure, localization, function, mechanism of catalysis, molecular size or nucleotide sequences<sup>23</sup>. In 1999, the classification of PLA<sub>2</sub> was updated. These PLA<sub>2</sub> group types are listed in **Table 2**. The secretory PLA<sub>2</sub>s are all low molecular mass enzymes (13-15 kDa) with a very rigid tertiary structure arising from the presence of 5-8 disulfide bridges<sup>23</sup>. Thus, they possess both stability against proteolysis and resistance to denaturation, which allows them to maintain activity in the extracellular fluids where they are found<sup>23</sup>.

**Table 2 Phospholipase A<sub>2</sub> groups**<sup>23</sup>

Group		Sources	Location	Size (kDa)	Ca <sup>2+</sup> requirement	Disulfides
I	A	Cobras, kraits	Secreted	13– 15	mM	7
	B	Porcine/ human pancreas	Secreted	13– 15	mM	7
II	A	Rattlesnakes, <b>vipers</b> , human synovial fluid/ platelets	Secreted	13– 15	mM	7
	B	Gaboon viper	Secreted	13– 15	MM	6
	C	Rat/ mouse testes	Secreted	15	MM	8
III		Bees, lizards	Secreted	16– 18	MM	5
IV	A	Raw 264.7/ rat kidney, human U937/ platelets	Cytosolic	85	< uM	
	B	Human brain	Cytosolic	100	< uM	
	C	Human heart/ skeletal muscle	Cytosolic	65	None	
V		Human/ rat/ mouse heart/ lung, P388D 1 macrophages	Secreted	14	MM	6
VI		P338D 1 macrophages, CHO cells	Cytosolic	80– 85	None	
VII	A	Human plasma	Secreted	45	None	
	B	Bovine brain	Cytosolic	42	None	
VIII		Bovine brain	Cytosolic	29	None	
IX		Marine snail	Secreted	14	MM	6
X		Human leukocytes	Secreted	14	mM	7

### 1.6. Multiple Isoenzymes of PLA<sub>2</sub>

The Russell's viper venom exhibits a geographical variation in the components of venom even within subspecies. Such as *D. russellii* venom from different regions of India was comparatively characterized<sup>25</sup>. The eastern region is more lethal potency than western, southern and northern, respectively. An interesting report indicated that variation of venom components from same snake species in close association with its diet<sup>26</sup>.

Recently, venoms from some subspecies of *D. russellii* have been chromatography performed and purified. Several PLA<sub>2</sub> isoenzymes have been found and their biological activities have been studied. For example, purified "RV-4" of *D. r. formosensis* in Taiwan was pre-synaptic blocker of neuromuscular nerve transmission, whereas RV-7 had much lower enzymatic activity and was not toxic<sup>22</sup>. In addition, purified VRV-IIIb from *D. russellii* in India could inhibit platelet aggregation<sup>19</sup>. PLA<sub>2</sub> from the other species have also various effects e.g. myotoxin PLA<sub>2</sub> from *Bothrops asper* cause of cytolytic and myotoxic<sup>27</sup>. However, EC-I-PLA<sub>2</sub> in Indian saw-scaled viper (*Echis carinatus*) was non-lethal to mice and devoid of neurotoxicity, myotoxicity, anticoagulant activity and cytotoxicity but induced mild edema in the foot of mice and inhibited platelet aggregation<sup>28</sup>. Difference of amino acid sequences, size of protein, number of disulfide bonds, folding of protein and conformation of enzyme loops determines the efficiency of enzyme action and presence/absence of various pharmacological functions<sup>29</sup>.

While most of PLA<sub>2</sub>s were isolated and purified from snake venom prior to numerous experiments such as crystallization, x-ray diffraction, biological activity of proteins and etc., the functional recombinant PLA<sub>2</sub> production was interested and attempted. Although Russell's vipers in Thailand are abundance, venom

utilizing has been limited because of the difficulty in maintain the snake in captivity. Thus, production of PLA<sub>2</sub>, a major lethal factor in venom, is alternative choice useful to the further PLA<sub>2</sub> studies or advance to specific antivenom decreasing side effects.

The venom composition is an important consideration because bites by divergent subspecies may explain the variety of symptomatology in viper bite from different countries. Thus, this research is aimed at screening PLA<sub>2</sub> isoforms of *Daboia russellii siamensis* in Thailand and to compare with other subspecies lead to knowledge about variation of clinical effects. In addition, this research was conducted to clone and express of recombinant PLA<sub>2</sub> to produce *in vivo* PLA<sub>2</sub> protein and to study their activities.

## 2. Research Questions

### Primary Question

How many PLA<sub>2</sub> isoforms of *Daboia russellii siamensis* in Thailand?

### Secondary Question

What is specific enzymatic activity value of recombinant PLA<sub>2</sub>?

## 3. Objective of This Research

1. To characterize cDNA, gDNA and deduced-amino acid sequences of PLA<sub>2</sub> of *Daboia russellii siamensis* in Thailand.
2. To produce functional recombinant PLA<sub>2</sub> protein useful to other studies.

#### 4. Hypothesis

PLA<sub>2</sub> of *Daboia russellii siamensis* in Thailand is different from PLA<sub>2</sub> of other subspecies.

#### 5. Keywords


Russell's viper

*Daboia russellii siamensis*

Phospholipase A<sub>2</sub>


Cloning

Expression



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## 6. Conceptual Framework



## 7. Expected Benefit & Application

1. Genetic information on PLA<sub>2</sub> of *Daboia russellii siamensis* in Thailand to PLA<sub>2</sub> will be useful for taxonomic classification of Russell's viper subspecies.

2. Recombinant is useful for studies of pathophysiology of Russell's viper bites, production of PLA<sub>2</sub>-specific antibody and aid in product of diagnostic kit for snake bites.



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## CHAPTER II

### LITERATURE REVIEW

#### 1. Potency of PLA<sub>2</sub> Isoforms

The venom of *Daboia russellii* is known to contain PLA<sub>2</sub>, which may contribute to the toxicity of the whole venom. This enzyme was constitution 70% of the whole venom proteins<sup>3,21</sup>. The potent PLA<sub>2</sub> in venom of some subspecies was biological activity studied following purified to homogeneity by few step of chromatography as well as gel filtration.

There are several reports reveal PLA<sub>2</sub> functions and clinical signs in tested animals. A major PLA<sub>2</sub> (VRV PL-VIIIa) which constitutes 24% of the whole *D. russellii* venom in India, contributes 45% of the total PLA<sub>2</sub> activity of the venom<sup>21</sup>. It shows neurotoxic symptoms and damages vital organs such as lung, liver and kidney with LD<sub>50</sub> value of 5.3 mg/kg body weight of mice<sup>21</sup> (the lethal potency of PLA<sub>2</sub>s are shown in **Table 3**).

A PLA<sub>2</sub> from *D. russellii* venom in India (VRV PL-VIIIb) inhibiting platelet aggregation induced neurotoxic symptoms in experiment mice with an i.p. LD<sub>50</sub> of 5.2 mg/kg<sup>19</sup>. It also induced edema in foot pads of mice but devoid of anticoagulant, myotoxic and direct haemolytic activities<sup>19</sup>.

The isolated daboiatoxin (DbTx), a major lethal factor showing strong PLA<sub>2</sub> activity, was purified to homogeneity from the venom of *D. r. siamensis* (Myanma)<sup>18</sup>. It constitutes 12% of total venom protein and is the main lethal component of Myanmar Russell's viper venom with an i.p. LD<sub>50</sub> (0.05 mg/kg) 12-fold greater than that of the whole venom (LD<sub>50</sub> i.p. 0.6 mg/kg)<sup>18</sup>. Unlike no neurotoxic features in Myanmar victims, DbTx induces neurotoxic symptoms in mice<sup>18</sup>. It is

possible that neurotoxicity of PLA<sub>2</sub> in mice dose not predict neurotoxicity in human. DbTx also exhibits potent edema-inducing activity and a strong myonecrotic activity, but no haemorrhagic activity<sup>18</sup>.

Furthermore, RV-4 and RV-7 from *D. r. formosensis* in Taiwan were neurotoxic and not toxic, respectively<sup>22</sup>. The deduced amino acid sequences of RV-4 and RV-7 were 92% identical to those of the vipoxin and vipoxin inhibitor, respectively, from *Vipera ammodytes ammodytes*<sup>22</sup>. Moreover, RV-7 inhibited the enzymatic activity of RV-4 *in vitro* but potentiated its neurotoxicity by reduce blocking time, and lethal potency<sup>22</sup>. The i.p. LD<sub>50</sub> of RV-4 and RV-4/RV-7 complex were estimated to be 0.32 and 0.15 mg/kg mice, respectively<sup>22</sup>. It is suggested that RV-7 may facilitate the specific binding of RV-4 to its presynaptic binding sites, probably by preventing its non-specific adsorption<sup>22</sup>.

The differences between PLA<sub>2</sub> isoenzymes in the same venom are not due to extent of glycosylation or any post-translational modifications<sup>11</sup>. Although some of the isoenzymes are closely related, recent studies of genomic sequencing have shown that these isoenzymes are derived from different genes and not by alternative splicing<sup>11</sup>.

**Table 3 Lethal potencies and specific enzymatic activities of viper PLA<sub>2</sub>.**

Protein	LD <sub>50</sub> (mg/kg mouse)	Enzymatic activity <sup>a</sup> (μmoles/min/mg of protein)
<i>D. r. russellii</i>		
VRV PL-VIIIa <sup>21</sup>	i.p. 5.3	0.111
Whole venom <sup>21</sup>	i.p. 4.1	0.060
VRV PL-VIIIb <sup>19</sup>	i.p. 5.2	0.472
VRV PL-V <sup>20</sup>	i.p. 1.8	0.056
VRV PL-VI <sup>20</sup>	i.p. 3.5	0.084

**Table 3 Lethal potencies and specific enzymatic activities of viper PLA<sub>2</sub>, (continued)**

Protein	LD <sub>50</sub> (mg/kg mouse)	Enzymatic activity <sup>a</sup> (μmoles/min/mg of protein)
<i>D. r. russellii</i>		
R1 <sup>9</sup>	i.v. >5.00	-
R2 <sup>9</sup>	i.v. 2.10	-
R3 <sup>9</sup>	i.v. >10.00	-
R2+R3 <sup>9</sup>	i.v. 0.15	-
<i>D. r. formosensis</i>		
RV-4 <sup>22</sup>	i.v. 0.32	304
RV-7 <sup>22</sup>	i.v. >10.00	2.4
RV-4+RV-7 <sup>22</sup>	i.v. 0.15	192
<i>D. r. siamensis</i> (Myanmar)		
Daboiatoxin <sup>18</sup>	i.p. 0.05	91.7±4.5
Whole venom <sup>18</sup>	i.p. 0.6	39.2±2
<i>V. a. ammodytes</i>		
Vipoxin A <sup>30</sup>	Nontoxic	-
Vipoxin B <sup>31</sup>	0.05-0.15	-
Ammodytin I2 <sup>32</sup>	Nontoxic	-
Ammodytoxin A <sup>33</sup>	i.v. 0.021	280
Ammodytoxin B <sup>34</sup>	i.v. 0.58	520
Ammodytoxin C <sup>35</sup>	i.v. 0.36	-

<sup>a</sup> Conditions used for enzymatic activity measurements vary greatly, so comparisons of values between references must be done with caution. Substrates include egg yolk, egg lecithin, synthetic phospholipids, etc. In some cases detergents (sodium deoxycholate, Triton X-100) were added. Titrimetric, colorimetric and turbidimetric methods were used. Calcium concentration = 1-40 mM. pH = 7.3-8. Temperature = 18-50<sup>o</sup>C. The common definition of 1 unit is a decrease of 0.01 in absorbance in 10 min by 1 mg of enzyme<sup>36</sup>.

## 2. Enzymatic Activity

Such PLA<sub>2</sub> enzymes vary in their lethal and pharmacological potencies from low lethality and no specificity of action to so toxic and so specific in their actions. It is more interested in the lethal potencies and their enzymatic activity than other enzymes in snake venoms<sup>36</sup>.

The previous report showed that there is no relationship between relative enzymatic activities of the PLA<sub>2</sub> enzymes and their LD<sub>50</sub> values<sup>37,38</sup>. The enzymatic activities of some PLA<sub>2</sub> are shown in **Table 3**. Enzymatic activity values were reported in either as  $\mu\text{moles}/\text{min}/\text{mg}$  of protein or as units. It is expressed as a decrease in absorbance per min and per  $\mu\text{g}$  of phospholipase<sup>36,39</sup>. This activity can be converted to  $\mu\text{moles}$  of fatty acid released per min and per mg of phospholipase by measuring the decrease in absorbance of 0.1 which obtained by 0.01 or 0.025  $\mu\text{moles}$  of acid<sup>39</sup>. Because conditions used for measuring the enzymatic activities varied greatly from one study to another (see footnote to **Table 3**), the cross-comparison of values obtained by different investigators must be done with great caution<sup>36</sup>.

## 3. Comparison of PLA<sub>2</sub> Sequences

The N-terminal amino acid sequence of some PLA<sub>2</sub>s were shown in **Table 4**<sup>9,18</sup>. This report indicated that *D. r. siamensis* contains at least 5 PLA<sub>2</sub> isoforms<sup>9</sup>. The PLA<sub>2</sub> R3 of *D. r. russellii* and S4 of *D. r. siamensis* are probably identical to F7 (previously named RV-7) of *D. r. formosensis*<sup>9</sup>. The neurotoxin PLA<sub>2</sub> R2 and S2 are also very similar to F4 (previously named RV-4)<sup>9</sup>. It is noted that the neurotoxicity of R2 is dependent on the presence of R3, while F4 or S2 is moderate neurotoxic itself<sup>9</sup>. However, identity between S2 of *D. r. siamensis* and neurotoxic F4

of *D. r. formosensis* do not explain the lack of neurotoxicity in Thai Russell's viper bites. On the other hand, R1 and S1 are non-neurotoxic<sup>9</sup>.

**Table 4 The N-terminal amino acid sequences of viper PLA<sub>2</sub> toxin<sup>9</sup>**

R1	NLFQFAEMIVKMTGKNPL-SYSDYGCYCGWGGKGGKPKQDATDRCCFVHDCC	
S1-2		(100%)
S1-1	Y GR FR A N	(86%)
F4	NLFQFARMINGKLGAFSVWNYISYGCYCGWGGQGTTPKDATDRCCFVHDCC	
R2		(100%)
S2		(100%)
S3	DA QE F K	(88%)
VpxB	K	(98%)
F7	NLFQFGEMILEKTGKEVVHSYAIYGCYCGWGGQGRAQDATDRCCFVHDCC	
R3		(100%)
S4		(100%)
RVV <sub>012</sub>		(100%)
VpxA	D Q A R AQ	(88%)
P1	SLLEFGKMILEETGKLAIIPSYSSYGCYCGWGGKGTTPKDATDRCCFVHDCC	
P2-1	M V F	(94%)
P2-2	V F	(96%)
P3	M V F D	(92%)
Amdx	M G NPLT F V	(84%)
DbTx	NFFQFAEMIVKMTGKEAVHS...	

**Note** R: PLA<sub>2</sub> isoforms from *D. r. russellii* (Pakistan)<sup>9</sup>

S: PLA<sub>2</sub> isoforms from *D. r. siamensis* (Thailand)<sup>9</sup>

F: PLA<sub>2</sub> isoforms from *D. r. formosensis* (Taiwan)<sup>9</sup>

P: PLA<sub>2</sub> isoforms from *D. r. pulchella* (Sri Lanka)<sup>9</sup>

RVV: PLA<sub>2</sub> isoform from *D. r. siamensis* (Thailand)<sup>40</sup>

Amdx: ammodytoxin from *Vipera ammodytes*<sup>9</sup>

DbTx: only 20 amino acid sequences of daboia toxin PLA<sub>2</sub> from *D. r. siamensis* (Myanmar)<sup>18</sup>

VpxA and VpxB: vipoxin from *Vipera ammodytes ammodytes*<sup>22</sup>

Several amino acid sequences were deduced from nucleotide sequences. For example, cDNA cloning and sequencing of *RV-4* and *RV-7* of Taiwan Russell's viper<sup>22</sup>. The deduced amino acid sequences of *RV-4* and *RV-7* are 80% similar to each other<sup>22</sup> (**Figure 5**).

```

          *           20           *           40           *
RV-7   : NLFQFGEMILEKTGKEV VHSYAIYGCYCGWGGQGRAQDATDRCCFVHDCCYGTVNDC : 57
RVV012 : NLFQFGEMILEKTGKEV VHSYAIYGCYCGWGGQGRAQDATDRCCFVHDCCYGTVNDC : 57
RV-4   : NLFQFARMINGKLGAFSVMNYISYGCYCGWGGQGTPKDATDRCCFVHDCCYGQVKGK : 57
        NLFQFgeMileKtGkevVhsYaiYGCYCGWGGQGraQDATDRCCFVHDCCYGtVndC

          60           *           80           *           100          *
RV-7   : NPKTATYSYSFENGDI VCGDNDICLRTVCECDRAAAICLGQNVNTYDKNY EYYSISH : 114
RVV012 : NPKTATYSYSFENGDI VCGDNDICLRTVCECDRAAAICLGQNVNTYDKNY EYYSISH : 114
RV-4   : NPKLATYSYSFQRGNI VCGRNGCLRTICECDRVAANCFHQNKNTYNK EYKELSSSK : 114
        NPKtAtYSYSF2nG1IVCGdN1lCLRT6CECDRaAAiClgQNvNTY1KnYe5ySiSh

          120
RV-7   : CTEESEQC : 122
RVV012 : CTEESEQC : 122
RV-4   : CRQRSEQC : 122
        Ct2eSEQC

```

**Figure 5** An alignment of deduced mature amino acid sequence PLA<sub>2</sub>s. RVV012; PLA<sub>2</sub> from *D. r. siamensis*<sup>40</sup>, *RV-7* and *RV-4*; PLA<sub>2</sub> from *D. r. formosensis*<sup>22</sup>.

#### 4. Production of Recombinant PLA<sub>2</sub>

The availability of the recombinant snake venom PLA<sub>2</sub> production system is great interest for several reasons<sup>41</sup>. First, snake venom contains numerous PLA<sub>2</sub> isoforms, among which some might constitute undesirable contaminants which could interfere with activity assays. The use of the recombinant PLA<sub>2</sub> should avoid such problems. Second, recombinant technology provides the possibility of producing mutants, which could be used for functional study. Finally, recombinant technique can also be utilized to achieve labeling of PLA<sub>2</sub>s with stable isotopes prior to other studies<sup>41</sup>.

Secreted PLA<sub>2</sub> have been produced in various organisms, including yeast, mammalian cells and bacteria, but snake venom PLA<sub>2</sub>s have been produced only in *Escherichai coli*, usually a convenient host in terms of rapidity and easiness<sup>41</sup>.

Production of recombinant PLA<sub>2</sub>s requires a correct N-terminal residue, which is essential for enzymatic activity and proper folding of the PLA<sub>2</sub>. Two different approaches have been used to generate appropriately cleaved PLA<sub>2</sub>s<sup>41</sup>. The first one consists of producing the PLA<sub>2</sub> as a short or long fusion protein which is further cleaved chemically or enzymatically<sup>41</sup>. The second requirement for producing recombinant active PLA<sub>2</sub> is the correct formation of the disulfide bridges<sup>41</sup>. In *E. coli*, these bonds cannot be formed in the cytoplasm and hence recombinant PLA<sub>2</sub>s produced as inclusion bodies must be refolded *in vitro*<sup>41,42</sup>. For example PLA<sub>2</sub> expression, *Vipera ammodytes ammodytes* AmmodytoxinA has been highly expressed with a long fusion protein. In addition, A-PLA<sub>2</sub> of *Agkistrodon halys* Pallas was expressed in *E. coli* with initiator Met<sup>37</sup>. This recombinant protein has been efficiently renatured with 27% activity of native enzyme<sup>37</sup>.




### 1.1.2. Plaque Lift Hybridization and Detection System

Hybond-N, Nylon membrane was purchased from Phamacia Biotech AB, USA.

North2South<sup>®</sup> Direct HRP Labeling and Detection Kit were purchased from PIERCE, USA.

### 1.1.3. *In Vivo* Single-clone Excision of the pBK-CMV Phagemid Vector from the ZAP Express Vector

ExAssist helper phage, provided in ZAP Express<sup>®</sup> cDNA Gigapack<sup>®</sup> III Gold Cloning Kit (Stratagene), was used for generating the pBK-CMV phagemid vector. Map of pBK-CMV phagemid vector is shown in **Figure 7**.



**Figure 7** Map of the pBK-CMV vector.

#### 1.1.4. Genotypes of *Escheracia coli* Strain

**XL1-Blue MRF<sup>r</sup> strain;**  $\Delta(\text{mcrA})183 \Delta(\text{mcrCB-hsdSMR-mrr})173$   
endA1 supE44 thi-1 recA1 gryA96 relA1 lac [F' proAB lacI<sup>q</sup>Z $\Delta$ M15 Tn10(Tet<sup>r</sup>)].

**XLOLR strain;**  $\Delta(\text{mcrA})183 \Delta(\text{mcrCB-hsdSMR-mrr})173$  endA1 thi-1  
recA1 gryA96 relA1 lac [F' proAB lacI<sup>q</sup>Z $\Delta$ M15 Tn10(Tet<sup>r</sup>)] Su<sup>-</sup> (nonsuppressing)  $\lambda^r$   
(lambda resistant).

#### 1.1.5. Enzymes

**Table 5 Restriction enzymes with their recognition sites, recommended buffer and manufacturer.**

Enzymes	Recognition sequence	Buffer	Manufacturer
<i>Xho</i> I	C <sup>^</sup> TCGAG	NEBuffer 2	New England Biolabs
<i>Eco</i> R I	G <sup>^</sup> AATTC	NEBuffer 2	New England Biolabs
<i>Bam</i> H I	G <sup>^</sup> GATCC	NEBuffer 2	New England Biolabs

**Note** ^ represents the cleavage sites of restriction enzymes.

#### 1.1.6. DNA Sequencing Reaction


ABI PRISM<sup>®</sup> BigDye<sup>™</sup> Terminator Cycle Sequencing Ready Reaction  
kit Version 2.0, was purchased from Applied Biosystems, USA.

### 1.2. PLA<sub>2</sub> Expression

#### 1.2.1. Expression in *E. coli*

##### 1.2.1.1. Plasmid Vector

pTrcHisA (Invitrogen), a vector containing N-terminal 6xHis tags, was used for expression of recombinant proteins in *E. coli*. Its physical map is shown in **Figure 8**.



**Figure 8 Map of the pTrcHisA expression vector.**

### 1.2.1.2. Synthetic Oligonucleotides (or Primers)

Oligonucleotides were purchased from Bio Service Unit, NSTDA, Thailand.

**Table 6 Oligonucleotides and their descriptions.**

Name	Sequence (5'-3')	$T_m$ ( $^{\circ}\text{C}$ )	Description
PLAF	CGGGATCCGGGAACCTTTTCCAGTT	50	Oligonucleotides for PCR amplification of $PLA_2$ gene with <i>EcoR</i> I and <i>BamH</i> I recognition sites.
PLAR	GGAATTCCTTAGCATTGCTCTGAC	48	
5'FPLA-4F	AGCCTGGAGGTGCTTCTGG	62	Oligonucleotides for full-length amplification.
5'FPLA-7F	AGCCTGGAGGTGCTTCTGA	60	
3'FPLA-R	TTTAGTGCAGAGCTGGCACC	62	
FPLA-R	CACTCACCGCAGACGATAT	58	
$T_3$	AATTAACCCTCACTAAAGGG	56	Sequencing primer from $T_3$ or $T_7$ promoters.
$T_7$	GTAATACGACTCACTATAGGGC	64	

**Note**

$T_m$  was calculated from the formula  $2^{\circ}\text{C} (A+T) + 4^{\circ}\text{C} (G+C)$ .

### 1.2.1.3. Enzymes

Taq DNA polymerase (Promega)

Pfu DNA polymerase (Promega)

T4 DNA ligase (USB)

*EcoR* I and *BamH* I were listed in Table 1.

### 1.2.1.4. DNA Purification from Gel Slice

QIAquick<sup>®</sup> Gel Extraction Kit was purchased from QIAGEN Inc., USA.

### 1.2.1.5. Genotypes of *Escheracia coli* Strain

**DH5 $\alpha$  strain;** supE44  $\Delta$ lacU169 (phi 80 lacZ  $\Delta$ M15) hsdR17 recA1 endA gyrA96 thi-1 relA1.

**TOP10 strain;** mcrA  $\Delta$ (mrr-hsdRMS-mcrBC) phi 80  $\Delta$ lac  $\Delta$ M15  $\Delta$ lacX74 deoR recA1 araD139  $\Delta$ (ara leu) 7697 galU galK  $\lambda^-$  rpsL endA1 mupG

## 1.2.2. Proteins Detection

### 1.2.2.1. Sodiumdodecylsulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)

Mini-PROTEAN<sup>®</sup> 3 Electrophoresis Cell was purchased from BIO-RAD Laboratories, USA.

Low molecular weight standard was purchased from Phamacia Biotech AB, USA.

### 1.2.2.2. Coomassie Brilliant Blue Staining

Coomassie Brilliant Blue R-250 was purchased from USB, USA.

### **1.2.2.3. Silver Staining**

Silver Staining Kit Protein was purchased from Phamacia Biotech AB, USA.

### **1.2.2.4. Western Blotting Hybridization**

Trans-Blot<sup>®</sup> SD semi-dry electrophoretic transfer cell (BIO-RAD Laboratories, USA) was used for transfer proteins from gel to membrane by electrophoresis.

Nitrocellulose membrane (BioTrace<sup>®</sup> NT) was purchased from Pall Gelman Science, USA.

Mouse Anti-His Antibody was purchased from Phamacia Biotech AB, USA.

Peroxidase-Conjugated Rabbit Anti-Mouse Antibody was purchased from DAKO.

3, 3'- diaminobenzidine (DAB) tetrahydrochloride was purchased from BIO BASIC, Inc., Canada.

### **1.2.3. Protein Purification by Using Immobilized Metal Affinity Chromatography (IMAC)**

TALON<sup>®</sup> Metal Affinity Resins was purchased from CLONTECH Laboratories, Inc., USA.

### **1.2.4. Refolding of Protein by Dialysis**

SnakeSkin<sup>®</sup> Dialysis Tubing, 10K MWCO was purchased from PIERCE, USA.

### 1.2.5. Concentration of Protein

Vivaspin concentrators were purchased from Vivascience Ltd., Germany.

### 1.2.6. Quantitative Assay of $PLA_2$ Protein

Bio-Rad protein assay was purchased from BIO-RAD Laboratories, USA.

### 1.2.7. $PLA_2$ Activity Test

Egg lecithin was purchased from Sigma.

## 1.3. Cloning of Genomic $PLA_2$ DNA (Isolation of Full-length $PLA_2$ )


pGEM<sup>®</sup>-Teasy vector system was purchased from Promega, USA.

Bacterial strains: *Escheracia coli*, **JM109 strain**, endA1, recA1, gyrA96, thi, hsdR17 (rk -, mk +), relA1, supE44, (lac-proAB), [F, traD36, proAB, laqI q Z M15].

## 1.4. Chemicals

All other chemicals used in this work were either analytical or molecular biology grades purchased from many suppliers (Sigma; BIO-RAD; Phamacia Biotech AB; USB; Scharlau Chemie, S.A. and Merck).

### Work Outline



## 2. Methods

### 2.1. Screening of *PLA*<sub>2</sub> Clones from ZAP Express cDNA Library

#### 2.1.1. Plaque-lift Hybridization

##### 2.1.1.1. Plating

The host bacteria, XL1-Blue MRF' cells, was prepared as follows. A single colony was inoculated into 3 ml of LB broth (1% w/v NaCl, 1% w/v tryptone, 0.5% w/v yeast extract, pH 7.0) with 10 mM MgSO<sub>4</sub> and 0.2% w/v maltose, incubated with shaking at 37°C overnight or to an OD<sub>600</sub> of 0.5-1.0. Then, the cells were spun at 600 rpm for 2 min and supernatant was discarded. The cells were diluted to an OD<sub>600</sub> of 0.5 with sterile 10 mM MgSO<sub>4</sub>. The lambda phage cDNA library was diluted in SM buffer (50 mM Tris-HCl pH 7.5, -NaCl, -MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.01% gelatin) and added the equivalent of 50,000 pfu/plate to 200 µl of host cells at an OD<sub>600</sub> of 0.5. The bacteria and phage mixture were then incubated at 37°C for 15 min to allow the phage to attach to the cells. Three ml of NZY top agar (0.5% w/v NaCl, 0.2% w/v MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.5% w/v yeast extract, 1% NZ amine (casein hydrolysate), 0.7% w/v agarose, pH 7.5) was added into the bacteria and phage mixture and immediately pored onto an NZY agar plate (0.5% w/v NaCl, 0.2% w/v MgSO<sub>4</sub>·7H<sub>2</sub>O, 0.5% w/v yeast extract, 1% NZ amine (casein hydrolysate), 1.5% w/v agar, pH 7.5). The plate was incubated overnight at 37°C.

##### 2.1.1.2. Lifting

After plating, the plate was chilled for 2 hours at 4°C to prevent the NZY top agar from sticking to the nitrocellulose membrane. The nitrocellulose membrane was placed onto the NZY agar plate for 2 min to allow the transfer of the phage particles to the membrane. Both of the membrane and plate were marked same position to return collect the interested clones. Following lifting step, the membrane

was denatured and neutralized by submerge into a denaturation solution (1.5 M NaCl and 0.5 M NaOH) for 2 min, and a neutralization solution (1.5 M NaCl and 0.5 M Tris-HCl, pH 8.0) for 5 min, respectively. The membrane was briefly submerged in a 0.2 M Tris-HCl, pH 7.5 and 2X SSC buffer solution (1.5 M NaCl, 0.15 M sodium citrate, pH 7.0) for 30 sec and blotted on a Whatman<sup>TM</sup> 3MM paper for 1-2 min. Finally, the membrane was baked in the oven at 80°C for 1.5-2 hours to crosslink the DNA to the membrane and stored at 4°C.

### 2.1.1.3. Probe Labeling

The *RVV012-PLA<sub>2</sub>* DNA fragment<sup>40</sup> which isolated from previous work and shared homology to RV-7 of Taiwan PLA<sub>2</sub> isoform, was prepared from PCR amplification was labeled by North2South<sup>®</sup> Direct HRP Labeling and Detection Kit as follows. One hundred ng of *PLA<sub>2</sub>* DNA fragments in 10 µl water were denatured at 95°C for 5 min and snapped cool for 5 min. Ten µl of North2South<sup>®</sup> Direct Stabilized HRP Label and 10 µl of North2South<sup>®</sup> Direct Reaction Buffer were added. After incubation at 37°C for 30 min, 30 µl of North2South<sup>®</sup> Direct Enzyme Stabilization Solution was added and mixed. The probe concentration was approximate 1.67 ng/µl.

### 2.1.1.4. Hybridization

Hybridization of the *PLA<sub>2</sub>*-cDNA on the membrane with a DNA probe was conducted by North2South<sup>®</sup> Direct HRP Labeling and Detection Kit under the following condition.

To pre-hybridization, equal volume of North2South<sup>®</sup> Direct Hybridization Buffer Component 1 and 2 were combined in a clean plastic plate at least 0.1 ml per cm<sup>2</sup> membrane. The hybridization solution was incubated at 55°C in a hybridization oven (HYBAID). After warming the hybridization solution at least 5 min, the blot-membrane was placed and pre-hybridized with gentle rotation for at least

15 min. Following the pre-hybridization step, about 5-10 ng of HRP-labeled DNA probe per ml of hybridization solution was added and incubated 1-4 hours with gentle rotation at 55°C. After hybridization, the membrane was washed 3 times with 0.5 ml per cm<sup>2</sup> membrane washing buffer 1 (2X SSC, 0.1% SDS) at 55°C for 5 min per each wash, performed same process with washing buffer 2 (2X SSC) at room temperature, and proceed to detection step.

#### **2.1.1.5. Detection**

The membrane was placed in a clean plastic bag containing equal volume of the North2South<sup>®</sup> Luminol/Enhancer Solution and North2South<sup>®</sup> Stable Peroxide Solution, incubated for 5 min at room temperature. After development, the solution was removed and the membrane was transferred and sealed in a new plastic bag. The chemiluminescent signals were detected by exposure to the X-ray film for 1 min.

#### **2.1.2. *In vivo* Single-clone Excision of the pBK-CMV Phagemid Vector from the ZAP Express Vector**

ZAP Expression vector with inserted DNA can be excised out of the phage in form of the kanamycin-resistant pBK-CMV phagemid vector by performance of the ExAssist helper phage into the host bacterial strains, XL1-Blue MRF' and XL0LR. The XL1-Blue MRF' strain can be co-infected with lambda phage cDNA library and helper phage, and secreted phagemid particles containing inserted DNA after helper phage procession. The XL0LR strain is designed to allow only the excised phagemid to replicate in the host, thus the ExAssist helper phage is unable to replicate its genome in this host cells. The XL0LR is also resistant to lambda phage infection,

so only pBK-CMV phagemid is replicated in host. *In vivo* single-clone excision was proceeded as described.

The plaques of  $PLA_2$  clones were obtained from 2 method. The first method was plaque-lift hybridization as described in section 2.1.1. The second method was Expressed Sequence Tags (ESTs) study in our lab. The interested plaques were cored from the agar plate and transferred to a sterile microcentrifuge tube containing 500  $\mu$ l SM buffer (50 mM Tris-HCl pH 7.5, 0.1 M NaCl, 10 mM  $MgSO_4 \cdot 7H_2O$ , 0.01% gelatin) and 20  $\mu$ l of chloroform. The content was vortexed to release the phage particles into the SM buffer, and incubated overnight at 4<sup>o</sup>C. The XL1-Blue MRF' cells and XLOLR cells were grown separately overnight in LB broth (1% w/v NaCl, 1% w/v tryptone, 0.5% w/v yeast extract, pH 7.0) with 10 mM  $MgSO_4$  and 0.2% (w/v) maltose, and in NZY broth (0.5% w/v NaCl, 0.2% w/v  $MgSO_4 \cdot 7H_2O$ , 0.5% w/v yeast extract, 1% NZ amine (casein hydrolysate), pH 7.5), respectively. Following inoculation, the cells were gently spun down at 6,000 rpm for 2 min and supernatant was discarded. The pellet was suspended in 10 mM  $MgSO_4$  to an  $OD_{600}$  of 1.0. One  $\mu$ l of the ExAssist helper phage was added into the mixture containing 60  $\mu$ l of XL1-Blue MRF' cells at an  $OD_{600}$  of 1.0 and 75  $\mu$ l phage stock of interested plaque in SM buffer. The reaction was incubated for 37<sup>o</sup>C for 15 min, and then 750  $\mu$ l of NZY broth was add and incubated at 37<sup>o</sup>C for 2-3 hours with shaking. After incubation, the mixture of bacteria and phage was heated at 65-70<sup>o</sup>C for 20 min and spun down at 600 rpm for 2 min. The supernatant was decanted into a new clean tube. This stock contains the excised pBK-CMV phagemid vector packaged as filamentous phage particle. The mixture of 100  $\mu$ l phage supernatant and 200  $\mu$ l freshly grown XLOLR cells was incubated at 37<sup>o</sup>C for 15 min. Three hundred  $\mu$ l of NZY broth was added and incubated at 45<sup>o</sup>C for 45 min. After incubation, the XLOLR cells were spread on LB-kanamycin agar plate (50  $\mu$ g/ml) and incubated overnight at 37<sup>o</sup>C.

### **2.1.3. Double Strand Phagemid DNA Extraction by Alkaline Lysis Method**

A single colony of bacteria was inoculated in 3 ml NZY broth and incubated at 37°C with 200 rpm shaking for 16-20 hr. The cells were harvested in 1.5 ml microcentrifuge tubes by centrifugation at 5,000 rpm for 3 min and then resuspended in 100 µl of solution I (50 mM glucose, 10 mM EDTA, 25 mM Tris-HCl, pH 8.0) with 20 µg/ml RNase A. To the cell suspension, 200 µl of freshly prepared solution II (1% SDS, 0.2 N NaOH) was added and incubated on ice for 5 min. Then, 150 µl of solution III (3 M potassium acetate, 11.5% glacial acetic acid) was added to the mixture and incubated on ice for 5 min. The mixture was pellet by centrifugation at 10,000 rpm for 10 min. The supernatant was decanted to a new tube. The phagemid DNA was recovered from the supernatant by adding 7/10 volume of isopropanol and standing in room temperature for 10 min. The content was centrifuged at 12,000 rpm for 10 min. The pellet was washed with 500 µl of 70% ethanol, centrifuged at 12,000 rpm for 5 min and dried at room temperature. The DNA pellet was resuspended in 30 µl of TE buffer pH 7.5 (10 mM Tris-HCl, pH 7.5; 1 mM EDTA) or sterile water.

### **2.1.4. Digestion of Restriction Endonucleases and Analysis**

About 500 ng of phagemid DNA was double-digested with 5 units of *EcoR* I and *Xho* I according to manufacturer's protocols (New England Biolabs), 1X reaction buffer (provided), 1X BSA and sterile distilled water to a final volume of 20 µl. The digestion was incubated at 37°C for 3 hours. After digestion, digested phagemids were fractionated on 1.2% agarose gel electrophoresis. Clones which containing of about 0.6 kb insertions, the expected size of mature *PLA*<sub>2</sub> cDNA, were selected for sequencing.

### 2.1.5. Sequencing

The PCR sequencing was performed by using BigDye<sup>TM</sup> Terminator Cycle Sequencing Ready Reaction kit. The PCR reaction was carried out in a 10 µl reaction containing 4.0 µl of terminator ready reaction mix, 3.2 pmol of sequencing primer and 500 ng DNA template. After incubation at 95°C for 2 min, amplification was carried out for 25 cycles with the following temperature cycling parameters; 95°C for 10 sec of denaturation, 50°C for 5 sec of annealing and 60°C for 4 min of extension. The DNA was then precipitated by the addition of 1/10 volume of 3 M sodium acetate and 2 volumes of absolute ethanol and incubated at -20°C for 1 hour. After centrifugation at 12,000 rpm for 10 min, the pellet was washed with 500 µl of 70% ethanol and air dried. The DNA pellet was resuspended in 10 µl Template Suppression Reagent (Perkin-Elmer) and loaded to the ABI PRISM sequencer.

### 2.1.6. Alignment and Computational Searching Sequences Analysis

The nucleotide sequences obtained from the clones of interest were compared against nucleotide sequences in online database by using BLAST N (Basic Local Alignment Search Tool) program via the World Wide Web. The sequences, which have significant homology to those of *PLA<sub>2</sub>* genes, were further analyzed.

Alignments of *PLA<sub>2</sub>* sequences were made using CLUSTAL X multiple alignment program.

## 2.2. PLA<sub>2</sub> Expression

### 2.2.1. Expression in *E. coli*

#### 2.2.1.1. Subcloning to Expression Vector

##### 2.2.1.1.1. PCR Amplification

Two primers, PLAF and PLAR, were designed from two conserved sequence among the PLA<sub>2</sub> isoforms (*RV-4* and *RV-7*)<sup>22</sup> downstream the signaling sequences. These primers also contain some restriction recognition sites at their 5' end (PLAF: *Bam*H I, PLAR: *Eco*R I) for facilitating the ligation to cloning vector.

The typical PCR reaction was carried out in a 25 µl reaction containing 1X PCR buffer, 1.25 units of Taq DNA polymerase (Promega), 1 µM of each primer, 1.5 mM MgCl<sub>2</sub>, 200 µM of each dNTPs and 200 ng DNA template. After incubation at 94°C for 2 min, amplification was carried out for 5 cycles with the following temperature cycling parameters: 94°C for 20 sec of denaturation, 48°C for 30 sec of annealing and 72°C for 30 sec of extension. Then, 30 cycles of the following temperature cycling parameters were performed: 94°C for 20 sec of denaturation, 60°C for 30 sec of annealing and 72°C for 30 sec of extension. The final amplification cycle included an addition of a 5 min extension at 72°C.

##### 2.2.1.1.2. DNA Purification from Gel Slice

After PCR, the amplified DNA fragments were purified by QIAquick<sup>®</sup> Gel Extraction Kit in order to remove impurities such as small RNA, proteins, unincorporated nucleotides or primers. A band of the DNA fragment of interest was excised from agarose gel with a clean, sharp razor blade. Three volumes of Buffer QG to one volume of gel (100 mg ~ 100 µl) was added and the tube was placed in a 50°C water bath incubator. After agarose gel was completely dissolved, one gel volume of

isopropanol was added, mixed and applied to the QIAquick column. After centrifugation at 10,000 xg for 1 min, the flow-through solution was discarded. The DNA fragments was washed with Buffer PE and centrifuged for 1 min. Buffer EB (10 mM Tris-HCl, pH 8.5) or distilled water was added to elute DNA and was then centrifuged for 1 min, stored at -20°C.

#### 2.2.1.1.3. Ligation of PCR Products into Plasmid Vector

After *Bam*H I and *Eco*R I-digestion of pTrcHisA vector and *PLA*<sub>2</sub> DNA, the digested DNA was purified from gel slice by QIAquick<sup>®</sup> Gel Extraction Kit as described in section 2.3.1.1.2 and ligation was proceeded under as follows. The ligation reaction was carried out in a 10 µl reaction mixture containing pTrcHisA vector and *PLA*<sub>2</sub> DNA in the molar ratio 1:3, 2 units of T4 DNA ligase and 1X buffer. An appropriate amount of sterile water was added to make the 10 µl final volume. The pTrcHisA vector is approximate 4.4 kb and supplied at 50 ng/µl. The amount of the DNA insert was calculated from the following equation:

$$\frac{\text{ng of vector} \times \text{size (kb) of insert}}{\text{size (kb) of vector}} \times \text{insert : vector molar ratio} = \text{ng of insert}$$

The ligation reaction was carried out at 16°C for 16-18 hours and the ligation products were used to transform *E. coli* competent cells prepared by CaCl<sub>2</sub> method.

#### **2.2.1.1.4. Preparation of *E. coli* Competent Cells by CaCl<sub>2</sub> Method**

A single colony of *E. coli* was inoculated into 3 ml of LB broth and incubated at 37°C with 200 rpm shaking for 16-20 hours. The overnight culture was diluted 1:100 into 100 ml of new LB broth and incubated at 37°C until an OD<sub>600</sub> of 0.4-0.5. The cell culture was chilled on ice for 10 min prior to pipetting the 10 ml aliquots of the culture into 15 ml sterile polypropylene tubes. The cells were pelleted by centrifugation at 4,000 rpm for 10 min at 4°C. After that, the pellet was suspended in 5 ml of ice-cold 0.1 M MgCl<sub>2</sub>, centrifuged, resuspended in 5 ml of ice-cold 0.1 M CaCl<sub>2</sub> and left on ice for 30 min to establish competency. Finally, after centrifugation, the pellet was resuspended in 750 µl of 15% v/v glycerol and 0.1 M CaCl<sub>2</sub>. The cells were kept in 200 µl aliquots at -80°C until required.

#### **2.2.1.1.5. Transformation of *E. coli* Competent Cells**

Two hundred µl of *E. coli* competent cells were mixed with 2 µl of ligation products and immediately placed on ice for 30 min. The cells were subjected to heat-shock at 42°C for 45 sec and placed on ice for an additional 3 min. The transformed cells were mixed with 800 µl of LB broth and incubated at 37°C for 1 hour with shaking at 200 rpm. Finally, 100 µl of the transformed culture was spread on a LB agar plate containing 50 µg/ml ampicillin and incubated at 37°C overnight.

After transformation, the pTrcHisA vectors containing *PLA<sub>2</sub>* DNA were extracted by alkaline lysis method as described in section 2.1.3. Then, PCR sequencing as described in section 2.1.5 was proceeded to ensure the correct *PLA<sub>2</sub>* sequences.

### 2.2.1.2. PLA<sub>2</sub> Expression by Induced with IPTG

A single colony of *E. coli* was inoculated into 20 ml of LB broth containing 50 µg/ml ampicillin and incubated at 37°C with 200 rpm shaking for 16-20 hours. The overnight culture was diluted 1:100 into 1 L of LB broth containing 50 µg/ml ampicillin and incubated at 37°C until an OD<sub>600</sub> of 0.6-0.7. Then 5 ml of cells was collected to be negative control. One mM of IPTG was added into the culture and incubated at 37°C with 180 rpm shaking for 16-20 hours. The cells were pelleted by centrifugation at 6,000 rpm for 10 min at 4°C. The pellet was washed twice with PBS buffer and proceed to sonication step.

### 2.2.1.3. Sonication

The pellet was suspended with 30 ml PBS buffer, pH 7.4 and vortexed. The cells were sonicated 3 times for 30 sec each time. The cell lysate was centrifuged at 12,000 rpm for 30 min, 4°C. Before the protein purification step, the lysate was washed 3 times with washing buffer 1 (0.5% v/v Triton X-100, 50 mM Tris-HCl pH 8.0, 100 mM NaCl) and centrifuged at 12,000 rpm for 20 min, 4°C and then washed twice with washing buffer 2 (50 mM Tris-HCl pH 8.0, 100 mM NaCl). The pellet was stored at -80°C.

## 2.3. Protein Purification by Using Immobilized Metal Affinity Chromatography (IMAC)

The pellet was suspended with 6 M Guanidine Buffer, pH 8.0 (6 M guanidine, 10 mM Tris-HCl, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 100 mM NaCl) and shaken at room temperature or 4°C for 1 hour. The suspension was centrifuged at 12,000 rpm for 30 min. The supernate was decanted and loaded into the column containing 6 M

guanidine buffer equilibrated-resin. The column was washed with 8 M Urea Buffer, pH 8.0 (8 M urea, 10 mM Tris-HCl, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 100 mM NaCl) and 8 M Urea Buffer, pH 7.0 (8 M urea, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 100 mM NaCl), respectively. Finally, the His-tagged protein was eluted with 50 ml Elution Buffer, pH 4.5 (8 M urea, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 100 mM NaCl, 20 mM MES) into 50 fractions with a flow rate of 0.5 ml/min. Fractionation was carried out at room temperature. Absorbancy of each protein elution was monitored at 280 nm.

## 2.4. Proteins Detection

### 2.4.1. Sodiumdodecylsulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)

Twelve percentage of Resolving gel and 3.85% of Stacking gel were freshly prepared as follows:

#### 12% of Resolving gel (1 page)

40% Acrylamide:Bisarylamide (19:1)	1.200 ml
3 M Tris-HCl, pH 8.8	0.504 ml
10% SDS	0.040 ml
Distilled water	2.223 ml
10% ammonium persulphate	0.030 ml
TEMED	0.002 ml

#### 3.85% of Stacking gel (1 page)

40% Acrylamide:Bisarylamide (19:1)	0.144 ml
0.5 M Tris-HCl, pH 8.8	0.375 ml
10% SDS	0.015 ml
Distilled water	0.954 ml
10% ammonium persulphate	0.011 ml

TEMED

0.001 ml

After gel setting, the protein samples were mixed with 1/4 volume of Reducing Sample Buffer (62.5 mM Tris-HCl, pH 6.8; 8% w/v SDS; 40% v/v glycerol; 0.005% Bromophenol Blue; 10% 2-mercaptoethanol), denatured at 95°C for 10 min and loaded into gel slots in submarine condition. Electrophoresis was performed at 100 volts for 80 min in 1X Running Buffer, pH 8.3 (0.25 M Tris-HCl, 1.92 M glycine, 1% w/v SDS).

#### 2.4.2. Coomassie Brilliant Blue Staining

The gel was soaked in Coomassie Brilliant Blue solution (0.25% w/v Coomassie Brilliant Blue R-250, 45% methanol, 10% glacial acetic acid) for 1 hour with gentle agitation. After the staining solution was removed, the destaining solution (10% glacial acetic acid, 30% methanol) was added and incubated for 2-3 hours. The destaining solution was changed 3-4 times during incubation. Lastly, the gel was wrapped in cellophane sheet and dried overnight at room temperature for preserving the gel.

#### 2.4.3. Silver Staining

Silver Staining Kit, Protein was used to increase sensitivity of the visualization allows detection of most proteins down to the nanogram range, which is 100 times more sensitive than Coomassie Brilliant Blue staining. All of solutions were freshly prepared and performed according to manufacturer's protocols at room temperature with constant gentle agitation as follows:

##### Fixing solution

Absolute ethanol	100.0 ml
Acetic acid glacial	25.0 ml

Make up to 250 ml with distilled water

#### **Sensitizing solution**

Sodium acetate	17.0 g
Absolute ethanol	75.0 ml
Glutaraldehyde (25% w/v)	1.25 ml
Sodium thiosulphate (5% w/v)	10.0 ml

Make up to 250 ml with distilled water

#### **Silver solution**

silver nitrate solution (2.5% w/v)	25.0 ml
Formaldehyde (37% w/v)	0.1 ml

Make up to 250 ml with distilled water

#### **Developing solution**

Sodium carbonate	6.25 g
Formaldehyde (37% w/v)	0.05 ml

Make up to 250 ml with distilled water

#### **Stopping solution**

EDTA- $\text{Na}_2 \cdot 2\text{H}_2\text{O}$	3.65 g
---	--------

Make up to 250 ml with distilled water

First of all, the gel was soaked in fixing solution for 30 min, then transferred to sensitizing solution for 30 min and washed 3 times with distilled water for 5 min each time. After washing step, the gel was soaked in silver solution for 20 min, and rinsed twice in distilled water for 1 min each time. The gel was developed by soak in developing solution for 2-5 min, stopped by transfer to stopping solution for 10 min, and washed in 3 times with distilled water for 5 min each time. Finally, the gel

was wrapped in cellophane sheet and dried overnight at room temperature for preserving the gel.

#### 2.4.4. Western Blotting Hybridization

After SDS-PAGE was performed completely, the proteins were transferred from polyacrylamide gel to nitrocellulose membrane. To overcome the inefficiency of capillary transfers, Trans-Blot<sup>®</sup> SD semi-dry electrophoretic transfer cell has been adopted for eluting proteins from polyacrylamide gel as follows. The gel and membrane were soaked in transfer buffer for 15 min. Both of equilibrated gel and wetted membrane were sandwiched between sheets of transfer buffer-soaked thick filter papers, and then were placed on Trans-Blot<sup>®</sup> SD cell. The gel sandwich was transferred at 20 volt for 40 min. The transfer efficiency can be monitored by staining the transferred gel with Coomassie Brilliant Blue staining or with Silver Staining Kit.

To hybridization, the marker lane was cut to stain with Coomassie Brilliant Blue for 10 min and destained with destaining solution until bands of marker were visualized. The another part of membrane was incubated in blocking solution (5% w/v skim milk in PBS buffer, pH 7.4) for 1 hour with gentle agitation and then was washed 3 times with PBS buffer, pH 7.4 for 3 min each time. The membrane was transferred to a new blocking solution and 1:3,000 dilution of Mouse Anti-His Antibody was added, and incubated at room temperature with gentle agitation for 1 hour. The membrane was washed 3 times with PBS buffer, pH 7.4 for 3 min each time. Then the membrane was soaked in a new blocking solution and 1:1,000 dilution of Peroxidase-Conjugated Rabbit Anti-Mouse Antibody was added, and incubated with gentle agitation for 1 hour. After washing step, the membrane was soaked in visualizing solution (1.66 mM 3, 3'- diaminobenzidine (DAB) tetrahydrochloride, 0.04% NiCl<sub>2</sub>, and 0.006% H<sub>2</sub>O<sub>2</sub>), and allowed to occur in dark for 5 min. Finally, the

solution was removed and the membrane was washed with PBS buffer, pH 7.4 and dried overnight.

## 2.5. Refolding of Protein by Dialysis

After protein purification, the SnakeSkin<sup>®</sup> Dialysis Tubing was used to eliminate denaturation buffer to refolding of protein correctly as follows. The SnakeSkin<sup>®</sup> Dialysis Tubing was presoaked in 1 mM EDTA pH 8.0 and closed the lower end of the SnakeSkin<sup>®</sup> Tubing with SnakeSkin<sup>®</sup> Dialysis Tubing Clips. The sample was poured into the SnakeSkin<sup>®</sup> Tubing and closed the open end with Clips. The SnakeSkin<sup>®</sup> Tubing containing sample was soaked in 100 volumes of the dialysate 1 (5 M urea, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 100 mM NaCl), 100 volumes of the dialysate 2 (2.5 M urea, 50 mM NaH<sub>2</sub>PO<sub>4</sub>, 125 mM NaCl), and 100 volumes of the dialysate 3 (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 150 mM NaCl), for 3 hours each, respectively. The dialysis process was carried out at 4°C. After dialysis step, the sample was collected and stored at 4°C.

## 2.6. Concentration of Protein by Concentrator

Following the refolding of protein, the diluted sample was concentrated by Vivaspin concentrator as follows. The sample was poured into the concentrator and centrifuged at 3,000 xg for 1 hours. The remained sample was collected and stored at 4°C.

## 2.7. Quantitative Assay of $PLA_2$ Protein

Five dilutions of bovine serum albumin standard (1-15  $\mu\text{g/ml}$ ) were prepared. Eighty  $\mu\text{l}$  of each dilution standard or sample solution was added into 20  $\mu\text{l}$  of Dye Reagent Concentrate (BIO-RAD). The reaction was incubated at room temperature for 5 min and measured at 595 nm.

## 2.8. $PLA_2$ Activity Test

The spectrophotometric method, based on the pH change due to the liberation of fatty acids, was used. This method was modified from Araujo AL and Radvanyi F<sup>39</sup> as follows. Four  $\mu\text{l}$  of the enzyme was added to the sample cuvette containing 62.5  $\mu\text{l}$  of reaction medium (100mM NaCl, 10 mM  $\text{CaCl}_2$ , 3.5 mM lecithin solubilised with 0.5% Triton X-100 and 0.055 mM phenol red adjusted to an optical density of 1.8-2.2 at 558 nm). The same volume of solution without the enzyme was added to the reference cuvette. The change in absorbance between the reference and sample cuvettes was read at 558 nm. Enzymatic activity is expressed as a decrease in absorbance per min and per  $\mu\text{g}$  of phospholipase. This activity can be converted to  $\mu\text{moles}$  of fatty acid released per min and per mg of phospholipase by measuring the decrease in absorbance of 0.1 which obtained by 0.01  $\mu\text{moles}$  of acid.

## 2.9. Cloning of Genomic $PLA_2$ DNA (Isolation of Full-length $PLA_2$ )

### 2.9.1. PCR Amplification

The primers, 5'FPLA-4F, 5'FPLA-7F and 3'FPLA-R, were designed from untranslated region of conserved sequences of the  $PLA_2$  isoforms (5'FPLA-4F and 5'FPLA-7F).

The PCR reaction was carried out in a 50  $\mu$ l reaction containing 1X pfu buffer with 2 mM MgSO<sub>4</sub>, 1.25 U of pfu DNA polymerase (Promega), 1  $\mu$ M of each primer, 200  $\mu$ M of each dNTPs and 1  $\mu$ g genomic DNA template. After incubation at 95 $^{\circ}$ C for 5 min, amplification was carried out for 30 cycles with the following temperature cycling parameters: 95 $^{\circ}$ C for 40 sec of denaturation, 59 $^{\circ}$ C for 30 sec of annealing and 72 $^{\circ}$ C for 4 min of extension. The final amplification cycle included an addition of a 5 min extension at 72 $^{\circ}$ C.

### **2.9.2. Ligation into pGEM-T Vector**

Such PCR products were amplified without A-tail overhang from pfu DNA polymerase, A-tailing was executed before the ligation step as follows. The reaction was carried out in a 10  $\mu$ l reaction mixture containing 1-7 purified PCR fragments, 1X Taq buffer, 2.5 mM MgCl<sub>2</sub>, 0.2 mM dATP, 5 units of Taq DNA polymerase and sterile water to final reaction volume 10  $\mu$ l. Then, the reaction was incubated at 70 $^{\circ}$ C for 30 min and the ligation was proceeded.

About 3-4  $\mu$ l of A-tailed PCR fragments were added into the mixture containing 50 ng of pGEM<sup>®</sup>-T Easy Vectors, 1X Rapid Ligation Buffer, 3 Weiss units of T4 DNA Ligase. An appropriate amount of sterile water was added to final reaction volume 10  $\mu$ l. The ligation reaction was carried out at 4 $^{\circ}$ C for 16-18 hours and the ligation products were used to transform *E. coli* competent cells prepared by CaCl<sub>2</sub> method and sequencing as described in section 2.2.1.1.5 and 2.1.5, respectively. Finally, the nucleotide sequences were compared with GENBANK database by using BLAST N program via the World Wide Web and alignments by using CLUSTAL X multiple alignment program.


## CHAPTER IV

### RESULTS

#### 1. Screening of $PLA_2$ Clones from cDNA Library

##### 1.1. Plaque-lift Hybridization


After hybridization with *RVV012-PLA<sub>2</sub>* probe and washing out at low stringency condition, 27 of about 300 plaques were positive. The hybridized membranes were exposed on an X-ray films as shown in **Figure 9**.



**Figure 9** Positive  $PLA_2$  clones in plaque lift hybridization which were shown on X-ray film.

## 1.2. Digestion of Restriction Endonucleases and Analysis of the pBK-CMV Phagemid Vector

After detection of  $PLA_2$  clones on x-ray film, the plaques of interest were cored from the agar plate. The linear DNA ZAP express with inserted clone was excised out of the phage in form of the pBK-CMV phagemid vector by performance of the ExAssist helper phage into the host bacterial strains by *in vivo* single-clone excision process. The phagemid DNA was double-digested with *EcoR* I and *Xho* I, and then fractionated on agarose gel electrophoresis to screen the clones which contain of about 0.6 kb insertions which is the expected size of mature  $PLA_2$  cDNA (**Figure 10**).



**Figure 10** An ethidium bromide stained agarose gel of double strand phagemid of pBK-CMV digested by *EcoR* I and *Xho* I. Lane M; 300 ng of 100 bp DNA ladder, lane 1 and 2; digested-pBK-CMV containing 0.6 kb inserted cDNA.

### 1.3. Sequence Alignment and Computational Searching Analysis

About 0.6 kb  $PLA_2$  cDNA clones were obtained from 2 methods. The first method was plaque-lift DNA hybridization using *RVV012* which was isolated from previous work as probe. Nine of  $PLA_2$  positive clones from hybridization were sequenced and only 2 forms of  $PLA_2$ , designated *PlaS1* and *PlaS2*, were found in 3 and 6 clones respectively. In the meantime, Expressed Sequence Tags (ESTs) study identified 17  $PLA_2$  cDNA sequences, as same as plaque-lift DNA hybridization, only *PlaS1* and *PlaS2* were found in 5 and 12 clones respectively.

The DNA sequence analysis and comparison with GENBANK database using the BLAST N program and alignment by CLUSTAL X showed that *PlaS1* and *PlaS2* are identical to *RV-4* (GENBANK accession number S29298) and *RV-7* (GENBANK accession number S29299) which found in Taiwan Russell's viper venom. An alignment of 596 nucleotide and 122 deduced amino acid sequences of *PlaS1* and *PlaS2* were shown in **Figure 11** and **12**, respectively. An alignment showed 86% nucleotide sequence identity and 65% amino acid sequence identity.

```

*      20      *      40      *      60      *
PlaS1 : AGCCTGGAGGTGCTTCTGGACCCCTTCAACTCTGAGAAAAGGCTGCCAGCTGTCTGGATTCAGGAGGATCAG : 73
PlaS2 : AGCCTGGAGGTGCTTCTGAAACCCCTTCAACTCTGAGAAAAGGCTGCCAACTGTCTGGATTCAGGAGGATCAG : 73
AGCCTGGAGGTGCTTCTG ACCCCTTCAACTCTGAGAAAAGGCTGCCA CTGTCTGGATTCAGGAGGATCAG

      80      *      100      *      120      *      140
PlaS1 : GACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCGTGAAGGGAAACCTTTTCCAGTTCCCGAGGATGATCAAC : 146
PlaS2 : GACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCGTTGAAGGGAAACCTTTTCCAGTTGGGGAGATGATCTTG : 146
GACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCGT GAAGGGAAACCTTTTCCAGTT G G GATGATC

*      160      *      180      *      200      *      22
PlaS1 : GGAAGCTGGGAGCAATTTTCTGTTGGAACTACATCTCTTACGGATGCTACTGCGGTGGGGGGCCCAAGGCA : 219
PlaS2 : GAAAGACGGGGAAGAAGTTGTTCAATTCCTAGCCATTTACGGATGCTACTGCGGTGGGGAGCCCAAGGCA : 219
G AAAG GGG A TGTT CTAC C TTACGGATGCTACTGCGGTGGGG GGCCAAGGCA

      0      *      240      *      260      *      280      *
PlaS1 : CGCCAAAGGACGCCACCGACCGCTGCTTCTGTCACGACTGCTGTTACGGGGAGTGAAAGCTGCAACCC : 292
PlaS2 : GGCACAGGACGCCACCGACCGCTGCTTCTGTCACGACTGCTGTTACGGGACAGTGAAATCACTGCAACCC : 292
G CA AGGACGCCACCGACCGCTGCTTCTGTCACGACTGCTGTTACGGG AGTGAA G CTGCAACCC

      300      *      320      *      340      *      360
PlaS1 : CAAACTGGCCATCTACTCCTACAGCTTTCAGAGAGGGGATATCGTCTGCGGAAGAAACAACGGTGCCTGAGG : 365
PlaS2 : CAAACGGCCACTATTCCTACAGCTTTCAGAACGGGGATATCGTCTGCGGAGACAACGACCTGTGCCTGAGG : 365
CAA GGCCA CTA TCCTACAGCTTT AGA GGG ATATCGTCTGCGGA AAC AC GTGCCTGAGG

*      380      *      400      *      420      *      4
PlaS1 : ACCATTTGTGAGTGGACAGGGTCGCGGCAAACTGCTTTCACAGAAATGAATACATACAACAAAGATATA : 438
PlaS2 : ACTGTTTGTGAGTGGACAGGGCCGCGGCAAACTGCTTTCACAGAAATGAATACATACGACAAAACCTATG : 438
AC TTTGTGAGTGGACAGGG CGCGGCAA CTGC TT CAGAAAT GAATACATAC ACAA A TAT

      40      *      460      *      480      *      500      *
PlaS1 : AGTTCCTCTCATCTCTAAATGCAGGCAGAGSTCAGAGCAATGCTAAGTCTCTGCAGGACGGGAAAAACCCCT : 511
PlaS2 : AGTACTACTCAATCTCTCATTCAGGCAGGASTCAGAGCAATGCTAAGTCTCTGCAGGACGGGAAAAACCCCT : 511
AGT C CTCA CTCT A TGCA G AG GTCAGAGCAATGCTAAGTCTCTGCAGGACGGGAAAAA CCCT

      520      *      540      *      560      *      580
PlaS1 : CCAATTACACAATTGTGGTTGTGTACTCTATTATTCTGAATGCAATACTGAGCAATAAACGGTGCCAGCTC : 584
PlaS2 : CCAATTACACAATTGTGGTTGTGTACTCTATTATTCTGAATGCAATACTGAGCAATAAACGGTGCCAGCTC : 584
CCAATTACACAATTGTGGTTGTG TACTCTATTATTCTGAATGCAATACTGAGCAATAAAC GGTGCCAGCTC

*
PlaS1 : TGCACTAAATCG : 596
PlaS2 : TGCACTAAATCG : 596
TGCACTAAATCG

```

**Figure 11** An alignment of nucleotide sequence of *PlaS1* and *PlaS2*. Identical nucleotides were highlighted. Start and stop codons were shown in boxes. The underlined is a signal sequence. An alignment showed 86% nucleotide sequence identity.

```

          *           20           *           40
PlaS1 : NLFQFARMINGKLGAFSVWNYISYGCYCGWGGQGTPKDATDRC : 43
PlaS2 : NLFQFGEMILEKTGKEVWHSYAIYGCYCGWGGQGRAQDATDRC : 43
        NLFQF  MI  K  G   V  Y  YGCYCGWGGQG   DATDRC

          *           60           *           80
PlaS1 : CFVHDCCYGGVKG CNPKLAIYSYSFQRGNIVCGRINNGCLRTIC : 86
PlaS2 : CFVHDCCYGTVND CNPKTATYSYSFENGDIVCGDNDLCLRTVC : 86
        CFVHDCCYG V  CNPK A YSYSF2 G1IVCG N1 CLRT6C

          *           100          *           120
PlaS1 : ECDRVAANCFHQNKNTYNKEYKFLSSSKCRQRSEQC : 122
PlaS2 : ECDRAAAICLGQNVNTYDKNYEYYSISHCTEESEQC : 122
        ECDR AA C  QN NTY1K Y 5 S S C 2 SEQC

```

**Figure 12** An alignment of deduced amino acid sequence of PlaS1 and PlaS2. Identical nucleotides were highlighted. An alignment showed 65% amino acid sequence identity.

สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย


## 2. $PLA_2$ Expression

### 2.1. Expression in *E. coli*


#### 2.1.1. Subcloning to Expression Vector

##### 2.1.1.1. PCR Amplification

Two primers, PLAF and PLAR, were designed from two conserved sequence among the  $PLA_2$  isoforms (*PlaS1* and *PlaS2*) downstream the signaling sequence. The PCR product size is 388 bp DNA in length (**Figure 13**). After that, the PCR products were purified and digested with restriction enzymes (*BamH* I and *EcoR* I) prior to perform the ligation.




สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย



**Figure 13** An ethidium bromide stained agarose gel showing the 388 bp of PCR products from pBK-CMV phagemid containing *PLA<sub>2</sub>*-cDNA by using PLAF and PLAR primers. Lane M; 300 ng of 100 bp DNA ladder, lane 1; *PlaS1* PCR product, lane 2; *PlaS2* PCR product.

### 2.1.1.2. Ligation of PCR Products into Plasmid Vector and Transformation of *E. coli* Competent Cells


The digested PCR product either *PlaS1* or *PlaS2* and pTrcHisA expression vector was ligated and transformed to the *E. coli* competent cells. After plasmid DNA extraction, each clone was analyzed by gel electrophoresis (**Figure 14**)



**Figure 14** An ethidium bromide stained agarose gel showing ligated-pTrcHis A expression vector with *PLA<sub>2</sub>* DNA. Lane 1 and 16; 300 ng of pTrcHisA expression vector without inserted DNA, lane 2-15; 300 ng of ligated-pTrcHisA expression vector with *PlaS2* DNA, lane 17-25; 300 ng of ligated-pTrcHisA expression vector with *PlaS1* DNA.

### 2.1.1.3. Digestion of Restriction Endonucleases and Analysis of the pTrcHisA Expression Vector Containing *PLA*<sub>2</sub> DNA

The selected clones from **Figure 14** which had shifted bands were double-digested with *EcoR* I and *BamH* I, and then fractionated on agarose gel electrophoresis to screen the clones which containing of 379 bp insertions (**Figure 15**). These clones were confirmed the correct sequences by sequencing to desired amino acid of protein (data not shown).




**Figure 15** An ethidium bromide stained agarose gel showing the digestion of ligated-pTrcHis A. Lane M; 300 ng of 100 bp DNA ladder, lane 1-4; 400 ng digested *PlaS2* in pTrcHisA, lane 5-7; 400 ng digested *PlaS1* in pTrcHisA.

### 2.1.2. Recombinant PLA<sub>2</sub> Expression by Induced with IPTG


The selected clones that have been confirmed by sequencing were expressed by inducing with IPTG. A single colony of *E. coli* containing recombinant PLA<sub>2</sub>, was inoculated in LB broth containing 50 µg/ml ampicillin and incubated at 37°C with 200 rpm shaking for 16-20 hours. The overnight culture was subcultured into 1 Litre of LB broth containing 50 µg/ml ampicillin and incubated at 37°C until an OD<sub>600</sub> of 0.6-0.7. A half mM of IPTG was added into the culture and incubated at 37°C with 180 rpm shaking for 3 hours. The cells were pelleted and heated prior to protein analysis by SDS-PAGE and Western blotting hybridization. In SDS-PAGE, Coomassie stained gel could not discriminate PLA<sub>2</sub> band between with or without IPTG induction. However, the Western blot showed that about 18 kDa of recombinant PlaS1 protein including extra amino acid from the vector, was expressed after inducing by IPTG. Surprisingly, in PlaS2 clone expression, about 23 kDa protein was exposed instead of 18 kDa protein (**Figure 16**). The other clones of *PlaS2* were also expressed at an equal size, 23 kDa, shown in **Figure 17**.

In addition, the optimization of IPTG concentration and incubation time after adding IPTG was performed. IPTG was added in range 0-2 mM, and incubated at 37°C, 180 rpm with shaking for 3 hours. The Western blot showed that at 1 mM concentration of IPTG is the best (**Figure 18**). The optimization of incubation time after adding IPTG in range 1 hour to overnight (16-18 hours), the highest PLA<sub>2</sub> expression was obtained in an overnight incubation as shown in **Figure 19**.


Furthermore, to compare the effect of host strain in PLA<sub>2</sub> expression, recombinant PLA<sub>2</sub> plasmids were transformed into DH5α and TOP10 strain. Similar recombinant PLA<sub>2</sub> expression was observed as shown in **Figure 20**.




**Figure 16** PlaS2 and PlaS1 expression inducing with 1 mM IPTG for 3 hours. **A;** Coomassie stained gel, **B;** Western blot. Lane 1; cells lysate of PlaS2, lane 2; cells lysate of PlaS2 without IPTG, lane 3; cells lysate of plasmid which has not  $PLA_2$ , lane 4; cells lysate of plasmid which has not  $PLA_2$  without IPTG, lane 5; cells lysate of PlaS1, lane 6; cells lysate of PlaS1 without IPTG.




**Figure 17** The other clones of PlaS2 inducing with 1 mM IPTG for 3 hours. **A;** Coomassie stained gel, **B;** Western blot. Lane 1; cells lysate of clone 2, lane 2; cells lysate of clone 2 with IPTG, lane 3; cells lysate of clone 3, lane 4; cells lysate of clone 3 without IPTG, lane 5; cells lysate of clone 4, lane 6; cells lysate of clone 4 without IPTG, lane 7; cells lysate of clone 5, lane 8; cells lysate of clone 5 without IPTG.



**Figure 18 Optimization of IPTG which incubation for 3 hours. A; Coomassie stained gel, B; Western blot. Lane 1; cells lysate of PlaS2 with 0.5 mM of IPTG, lane 2; cells lysate of PlaS2 with 1 mM of IPTG, lane 3; cells lysate of PlaS2 with 2 mM of IPTG, lane 4; cells lysate of PlaS2 without IPTG, lane 5; cells lysate of PlaS1 with 0.5 mM of IPTG, lane 6; cells lysate of PlaS1 with 1 mM of IPTG, lane 7; cells lysate of PlaS1 with 2 mM of IPTG, lane 8; cells lysate of PlaS1 without IPTG.**



**Figure 19 Optimization of incubation time after adding 1 mM of IPTG. A; Coomassie stained gel, B; Western blot. Lane 1; incubated 1 hour cells lysate of PlaS2, lane 2; incubated 3 hours cells lysate of PlaS2, lane 3; incubated 5 hours cells lysate of PlaS2, lane 4; incubated overnight cells lysate of PlaS2, lane 5; incubated overnight cells lysate of PlaS2 without IPTG, lane 6; incubated 1 hour cells lysate of PlaS1, lane 7; incubated 3 hours cells lysate of PlaS1, lane 8; incubated 5 hours cells lysate of PlaS1, lane 9; incubated overnight cells lysate of PlaS1.**




**Figure 20** Comparison of PLA<sub>2</sub> expression between DH5 $\alpha$  and TOP10 strain that were induced with 1 mM of IPTG for overnight. **A**; Coomassie stained gel, **B**; Western blot. Lane 1; cells lysate of PlaS2 in TOP10, lane 2; cells lysate of PlaS2 in TOP10 without IPTG, lane 3; cells lysate of PlaS2 in DH5 $\alpha$ , lane 4; cells lysate of PlaS1 in TOP10, lane 5; cells lysate of PlaS1 in TOP10 without IPTG, lane 6; cells lysate of PlaS1 in DH5 $\alpha$ .

### 2.1.3. Sonication


After cells culture, the cells in PBS buffer were sonicated 3 times for 30 sec. The cell lysate was centrifuged at 12,000 rpm for 30 min, 4°C. The supernate and pellet parts were analyzed by SDS-PAGE. Majority of recombinant PLA<sub>2</sub> protein was observed in the pellet part as inclusion bodies (**Figure 21** and **22**).



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย



**Figure 21 Recombinant PlaS1 expression after sonication. A; Coomassie stained gel, B; Western blot. Lane 1; before sonication, lane 2; after sonication, lane 3; supernate after sonication, lane 4; pellet after sonication, lane 5; cells lysate without IPTG.**



**Figure 22 Recombinant PlaS2 expression after sonication. A; Coomassie stained gel, B; Western blot. Lane 1; cells lysate without IPTG, lane 2; before sonication, lane 3; supernate after sonication, lane 4; pellet after sonication.**

### 3. Protein Purification by Using Immobilized Metal Affinity Chromatography (IMAC)

The pellet was suspended with 6 M Guanidine Buffer, pH 8.0. After centrifuged at 12,000 rpm for 30 min, the supernate was loaded into the column containing 6 M guanidine buffer equilibrated-resin. The column was washed with 8 M Urea Buffer, pH 8.0 and 8 M Urea Buffer, pH 7.0, respectively. The His-tagged protein was eluted with 50 ml Elution Buffer, pH 4.5, into 50 fractions with a flow rate of 0.5 ml/min. Absorbancy of each protein elution was monitored at 280 nm. No major peak was obtained in absorbant chromatogram (**Figure 23**). However, recombinant PLA<sub>2</sub> protein bands was observed in some fractions by using Western blot (**Figure 24**).





Figure 23 Absorbant chromatogram of purified recombinant PlaS1 fractions.




**Figure 24** Western blot of purified recombinant PlaS1 fractions. Lane 1; fraction 7, lane 2; fraction 8, lane 3; fraction 11, lane 4; fraction 12, lane 5; fraction 13, lane 6; fraction 15, lane 7; fraction 27, lane 8; fraction 28.

#### 4. Refolding of Protein by Dialysis

The SnakeSkin<sup>®</sup> Dialysis Tubing was used to eliminate denaturation buffer to refolding of protein. About 37 ml of purified recombinant PLA<sub>2</sub> fractions from 1.75 Litre of cell culture, proved contain PLA<sub>2</sub> protein by Western blot, were dialysis. Final volume after dialysis was increased to 45 ml.

#### 5. Concentration of Protein by Concentrator

The diluted protein sample was concentrated by Vivaspin concentrator. After centrifugation, the volume of remaining protein sample was reduced to about 230  $\mu$ l. A silver stained gel showed before and after concentrated sample (**Figure 25**). PlaS1 protein of the concentrated sample was present while it was absent in the passed-through. Thus, almost refolded PlaS1 was recovered.




**Figure 25** A silver stained gel of PlaS1. Lane 1; 1:400 volume of pooled PlaS1 before concentration, lane 2; 1:62 volume of concentrated PlaS1, lane 3; 1:400 volume of passed through the filter-solution after concentration.

## 6. Quantitative Assay of Recombinant PlaS1 Protein

Five dilutions of bovine serum albumin standard (0.8-12  $\mu\text{g/ml}$ ) were plotted a standard curve (**Figure 26**). Absorbency average 0.098 at 595 nm of diluted 2.8 times protein sample was calculated concentration of protein equal to 4.29  $\mu\text{g/ml}$ . Therefore, undiluted PlaS1 protein was 15.01  $\mu\text{g/ml}$  or 3.45  $\mu\text{g}/230 \mu\text{l}$  of concentrated total volume. The yield of purified protein at this step was about 2.0  $\mu\text{g}/\text{Litre}$  culture.



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย



**Figure 26 Standard curve of protein concentration.**


สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## 7. PLA<sub>2</sub> Activity Test

The spectrophotometric method, based on the pH change due to the liberation of fatty acids, was used. Sixty ng of PLA<sub>2</sub> enzyme was added to the sample cuvette containing 62.5  $\mu$ l of reaction medium (100mM NaCl, 10 mM CaCl<sub>2</sub>, 3.5 mM lecithin solubilised with 0.5% Triton X-100 and 0.055 mM phenol red adjusted to an optical density of 1.8-2.2 at 558 nm). The same volume of buffer without the enzyme or 60 ng BSA negative control protein was added to the reference cuvette. While the buffer without and BSA protein can not change absorbancy at 558 nm, an absorbancy of PLA<sub>2</sub> was dramatically decreased (**Table 7** and **Figure 27**).

**Table 7 Absorbancy values of PLA<sub>2</sub> activity test.**

Min Sample	0	10 sec	1	2	3	4	5	6	7	8	9	10
Buffer	2.096	2.124	2.110	2.121	2.183	2.186	2.070	2.096	2.124	2.185	2.056	2.131
PLA <sub>2</sub>	2.124	1.160	1.077	1.058	1.015	1.110	1.097	1.052	1.121	1.088	1.038	1.010
BSA	2.124	2.045	2.124	2.086	1.997	2.030	2.070	1.978	1.978	2.010	2.032	1.992



**Figure 27 Absorbance of PLA<sub>2</sub> activity test by spectrophotometric method.**

สถาบันวิจัยชีวการ  
จุฬาลงกรณ์มหาวิทยาลัย

The  $PLA_2$  activity was calculated from a decrease in absorbance per min and per  $\mu\text{g}$  of phospholipase. The enzymatic activity of expressed  $PLA_2$  was 1.86 units at 10 min.

$$A_{558} \text{ at 0 min} = 2.124$$

$$A_{558} \text{ at 10 min} = 1.010$$

Enzymatic activity

$$\begin{aligned} \Delta A_{558}/\text{min} \times \mu\text{g} &= (2.124 - 1.010)/10 \text{ min} \times 0.06 \mu\text{g} \\ &= 1.86 \text{ Units} \end{aligned}$$


The enzymatic activity was converted to 185.67  $\mu\text{moles}$  of fatty acid released per min and per mg of phospholipase by measuring the decrease in absorbance of 0.1 that obtained by 0.01  $\mu\text{moles}$  of acid.

$$\begin{aligned} \mu\text{moles}/\text{min} \times \text{mg} &= 0.01 \times (2.124 - 1.010)/0.1(10 \text{ min} \times 6 \times 10^{-5} \text{ mg}) \\ &= 185.67 \end{aligned}$$

## 8. Cloning of Genomic $PLA_2$ DNA (Isolation of Full-length $PLA_2$ )

### 8.1. PCR Amplification


Two primer sets, 5'FPLA-4F or 5'FPLA-7F and 3'FPLA-R, were designed from untranslated region of two conserved sequence among the  $PLA_2$  isoforms (5'FPLA-4F and 5'FPLA-7F). The PCR product size is about 2.0 kb DNA in length (**Figure 28**). After that, the PCR products were purified and digested with restriction enzymes (*EcoR* I) prior to perform the ligation.



**Figure 28** An ethidium bromide stained agarose gel showing the PCR products from genomic DNA using 5'FPLA-4F or 5'FPLA-7F and 3'FPLA-R primers. Lane M; 300 ng of 1 kb DNA ladder, lane 1; 5'FPLA-4F and 3'FPLA-R primers, lane 2; 5'FPLA-7F and 3'FPLA-R primers.

## 8.2. Digestion of Recombinant pGEM-T with Restriction Endonuclease

After ligation and transformation, the recombinant pGEM-T plasmids were digested with *EcoR* I. On agarose gel showed that pGEM-T plasmids contain size variation of insert DNA (**Figure 29**).



**Figure 29** An ethidium bromide stained agarose gel showing the digested pGEM-T plasmids. Lane M; 300 ng of 100 bp DNA ladder, lane 1-10; digested pGEM-T plasmid clone 1-10.

### 8.3. Sequence Alignment and Computational Searching Analysis

The DNA sequence were analyzed and compared to the entries in database using the BLAST N and CLUSTAL X program. From 7 selected clones, there were 3 clones of full-length PLA<sub>2</sub> with length of about 2 kb and 4 clones of non specific genes with length less than 2 kb. Three clones of full-length PLA<sub>2</sub> were designated *gPlaS1*, *gPlaS2* and *gPlaS3*. The highest BLAST score of *PlaS1* showed homologous to *Vipera aspis zinnikeri* vaspin B, accession number AY158635 (**Figure 30**). Whereas the highest BLAST score of *gPlaS2* and *gPlaS3* showed homologous to *Vipera aspis aspis* ammodytin I2, accession number AY158637 (**Figure 31-32**). An alignment between nucleotide sequences of *gPlaS1*, *gPlaS2* and *gPlaS3* showed 87% (*PlaS1:PlaS2*), 88% (*PlaS1:PlaS3*) and 98% (*PlaS2:PlaS3*) nucleotide sequence identity (**Figure 33**). Exon 1 encode 5' UTR, exon 2 encodes most of the signal peptide, and exon 3-5 encode regions of protein residues 1-43, 43-76, 76-122 and 3' UTR, respectively. The comparison between genomic DNA sequence of *gPlaS1* and its cDNA sequence, *PlaS1*, indicated that the coding and untranslated regions are identical (**Figure 34**). This observation was also found for *gPlaS2* and *PlaS2*. However, cDNA sequence encoded by *gPlaS3* could not be obtained, therefore, no comparison were shown. An alignment of deduced amino acid sequences of *gPlaS1*, *gPlaS2* and *gPlaS3* showed 69%(*gPlaS1:gPlaS2*), 70%(*gPlaS1:gPlaS3*) and 92%(*gPlaS2:gPlaS3*) amino acid sequence identity (**Figure 35**).

By using the BLAST P program, deduced amino acid sequence of *PlaS3* was highest homologous to Phospholipase A2 RV-7 precursor, accession number P31100 (**Figure 36**). Comparison of deduced amino acid sequences of *gPlaS1*, *gPlaS2*, *gPlaS3* with other N-terminal amino acid sequences *D. russellii* PLA<sub>2</sub> reports showed that *gPlaS3* showed some amino acid differences from the other (**Figure 37**).

Comparison between cDNA and gDNA showed that PLA<sub>2</sub> gene has 5 exons and 4 introns (**Figure 38**).

Sequences producing significant alignments:				Score	E
				(bits)	Value
gi 33187117 gb AY158635.1	Vipera aspis zinnikeri vaspin B ...	1285	0.0		
gi 33187115 gb AY158634.1	Vipera aspis vaspin B (VaspB) ge...	1285	0.0		
gi 33187139 gb AY243575.1	Vipera aspis aspis vaspin B isof...	1285	0.0		
gi 33187137 gb AY243574.1	Vipera aspis zinnikeri vaspin B ...	1285	0.0		
gi 33187143 gb AY243577.1	Vipera aspis zinnikeri vaspin B ...	1277	0.0		
gi 33187141 gb AY243576.1	Vipera aspis aspis vaspin B isof...	1269	0.0		
gi 33187113 gb AY152843.1	Vipera aspis zinnikeri vaspin A ...	815	0.0		
gi 33187751 gb AF548351.1	Vipera aspis vaspin A (vaspA) ge...	815	0.0		
gi 33187119 gb AY158636.1	Vipera berus berus phospholipase...	682	0.0		
gi 33187133 gb AY159810.1	Vipera aspis zinnikeri ammodytin...	678	0.0		
gi 33187129 gb AY159808.1	Vipera aspis ammodytin I1 isofo...	678	0.0		
gi 33187127 gb AY159807.1	Vipera aspis aspis ammodytin I1 ...	678	0.0		
gi 33187131 gb AY159809.1	Vipera aspis ammodytin I1 isofo...	662	0.0		


**Figure 30** Homology searching via Internet result of *gPlaS1* by using BLAST N program at [www.ncbi.nlm.nih](http://www.ncbi.nlm.nih).

Sequences producing significant alignments:				Score	E
				(bits)	Value
gi 33187121 gb AY158637.1	Vipera aspis aspis ammodytin I2 ...	1144	0.0		
gi 6967297 emb X84018.1 VAMMI2	V.ammodytes ammodytin I2 gene	1082	0.0		
gi 33187113 gb AY152843.1	Vipera aspis zinnikeri vaspin A ...	1049	0.0		
gi 33187751 gb AF548351.1	Vipera aspis vaspin A (vaspA) ge...	1049	0.0		
gi 33187125 gb AY158639.1	Vipera berus berus ammodytin I2 ...	825	0.0		
gi 13936540 gb .1 AF253048	Vipip8 Vipera ammodytes ammodyt...	783	0.0		
gi 33187135 gb AY159811.1	Vipera berus berus ammodytin I1 ...	775	0.0		
gi 33187123 gb AY158638.1	Vipera aspis ammodytin I2 (AmtI2...	769	0.0		
gi 33187131 gb AY159809.1	Vipera aspis ammodytin I1 isofo...	767	0.0		
gi 3885849 gb AF091855.1 AF091855	Vipera palaestinae VP7 ph...	747	0.0		
gi 3885847 gb AF091854.1 AF091854	Vipera palaestinae VP8 ph...	686	0.0		
gi 33187119 gb AY158636.1	Vipera berus berus phospholipase...	674	0.0		
gi 33187129 gb AY159808.1	Vipera aspis ammodytin I1 isofo...	642	0.0		
gi 33187127 gb AY159807.1	Vipera aspis aspis ammodytin I1 ...	642	0.0		

**Figure 31 Homology searching via Internet result of *gPlaS2* by using BLAST N program at [www.ncbi.nlm.nih](http://www.ncbi.nlm.nih).**

Sequences producing significant alignments:				Score	E
				(bits)	Value
gi 33187121 gb AY158637.1	Vipera aspis aspis ammodytin I2 ...	1136	0.0		
gi 6967297 emb X84018.1 VAMMI2	V.ammodytes ammodytin I2 gene	1074	0.0		
gi 33187113 gb AY152843.1	Vipera aspis zinnikeri vaspin A ...	997	0.0		
gi 33187751 gb AF548351.1	Vipera aspis vaspin A (vaspA) ge...	997	0.0		
gi 33187125 gb AY158639.1	Vipera berus berus ammodytin I2 ...	825	0.0		
gi 13936540 gb AF253048.1 AF253048	Vipera ammodytes ammodyt...	783	0.0		
gi 33187135 gb AY159811.1	Vipera berus berus ammodytin I1 ...	775	0.0		
gi 33187123 gb AY158638.1	Vipera aspis ammodytin I2 (AmtI2...	769	0.0		
gi 33187131 gb AY159809.1	Vipera aspis ammodytin I1 isofo...	767	0.0		
gi 3885849 gb AF091855.1 AF091855	Vipera palaestinae VP7 ph...	747	0.0		
gi 3885847 gb AF091854.1 AF091854	Vipera palaestinae VP8 ph...	686	0.0		
gi 33187119 gb AY158636.1	Vipera berus berus phospholipase...	674	0.0		
gi 33187129 gb AY159808.1	Vipera aspis ammodytin I1 isofo...	642	0.0		
gi 33187127 gb AY159807.1	Vipera aspis aspis ammodytin I1 ...	642	0.0		

**Figure 32 Homology searching via Internet result of *gPlaS3* by using BLAST N program at [www.ncbi.nlm.nih](http://www.ncbi.nlm.nih).**



**Figure 33** An alignment of nucleotide sequences of *gPlaS1*, *gPlaS2* and *gPlaS3*. Identical nucleotides were highlighted. Gaps have been introduced to optimize the alignment. Arrows indicated exon separation. Start and stop codons were shown in boxes. The underlined is a signal sequence.




Figure 33 (continued)

```

PlaS1-cDNA AGCCTGGAGGTGCTTCTGGACCCCTTCAACTCTGAGAAAAGGCTGCCAGCT-----
PlaS2-cDNA AGCCTGGAGGTGCTTCTGAACCCCTTCAACTCTGAGAAAAGGCTGCCAACT-----
PlaS1-DNA AGCCTGGAGGTGCTTCTGGACCCCTTCAACTCTGAGAAAAGGCTGCCAGCTGTAAGTAGCCCCATCTTGGCCAT
PlaS2-DNA AGCCTGGAGGTGCTTCTGAACCCCTTCAACTCTGAGAAAAGGCTGCCAACTGTAAGTAGCCCCATCTTGGCCAT
PlaS3-DNA AGCCTGGAGGTGCTTCTGGACCCCTTCAACTCTGAGAAAAGGCTGCCAGCTGTAAGTAGCCCCATCTTGGCCAT

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA TTTCCCCTGCCCGGCTTCTCCTTCGGATGCTTGCTGCAGGTTATCCTTGACTTACAACCGTTTGTTTAGTGACC
PlaS2-DNA TTGTCCTGCCCGGCTTCTCCTTCGGATGCTTGCTGCAGGTTATCCTTGACTTACAACCGTTTGTTTAGTGACC
PlaS3-DNA TTTCCCCTGCCCGGCTTCTCCTTCGGATGCTTGCTGCAGGTTATCCTTGACTTACAACCGTTTGTTTAGTGACC

PlaS1-cDNA -----GTCTGGATTCT
PlaS2-cDNA -----GTCTGGATTCT
PlaS1-DNA CTTCTAGGGCCACTTTCCAGACTTTTACCAGCGGAGGCAATTAATGGGGTCTGTTCAATTCCAGGTCTGGATTCT
PlaS2-DNA CTTCTAGGGCCACTTTCCAGACTTTTACCAGCGGAGGCAATTAACGGGGTCTGCTCATTTCCAGGTCTGGATTCT
PlaS3-DNA CTTCTAGGGCCACTTTCCAGACTTTTACCAGCGGAGGCAATTAATGGGGTCTGTTCAATTCCAGGTCTGGATTCT

PlaS1-cDNA AGGAGGATGAGGACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCG-----
PlaS2-cDNA AGGAGGATGAGGACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCG-----
PlaS1-DNA AGGAGGATGAGGACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCGGTGAGTGAAGAAAAACAGTAAAATGGGCCA
PlaS2-DNA AGGAGGATGAGGACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCGGTGAGTGAAGAAAAACAGTAAAATGGGCCA
PlaS3-DNA AGGAGGATGAGGACTCTCTGGATAGTGGCCGTGTGCCTGATAGGCGGTGAGTGAAGAAAAACAGTAAAATGGGCCA

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA GCTAGTTCTGCTCTCTTTGCAGAAGGTAAAATGGAGGGTTACAGGTTGTCTTTGAGCGAGGCATGATGTACCCA
PlaS2-DNA GCTAGTTCTGCTCTCTTTGCAGAAGGTAAAATGGAGGGATTACAGGTTGTCTTTGAGCGAGGCATGATGTACCCA
PlaS3-DNA GCTAGTTCTGCTCTCTTTGCAGAAGGTAAAATGGAGGGTTACAGGTTGTCTTTGAGCGAGGCATGATGTACCCA

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA CATCACGTTTGTCTGTGGTCGTTAAGCGAGGACTGCCAGCATCTGCCATTAACCTACAGAGAAGTCGAGGGAGG
PlaS2-DNA CATCACGTTTGTCTGTGGTCGTTAAGCGAGGACTGCCAGCATCTGCCATTAACCTACAGAGAAGTCGAGGGAGG
PlaS3-DNA CATCACGTTTGTCTGTGGTCGTTAAGCGAGGACTGCCAGCATCTGCCATTAACCTACAGAGAAGTCGAGGGAGG

PlaS1-cDNA -----TCGAAGGGAACCTTTTCCAGTTTCGCGAGGATGATCAACGGAAAGCTGGGGAG
PlaS2-cDNA -----TTGAAGGGAACCTTTTCCAGTTTGGGGAGATGATCTTGGAAAAGACGGGGGA
PlaS1-DNA -TGAAACTTTCTCTCTTTTCCAGTCGAAGGGAACCTTTTCCAGTTTCGCGAGGATGATCAACGGAAAGCTGGGGAG
PlaS2-DNA -TGAAACTTTCTCTCTTTTCCAGTTGAAGGGAACCTTTTCCAGTTTGGGGAGATGATCTTGGAAAAGACGGGGGA
PlaS3-DNA CTGAAACTTTCTCTCTTTTCCAGTCGAAGGGAACCTTTTCCAATTCGGGGACATGATCAACAAAAGACGGGGGA

PlaS1-cDNA CATTTTCTGTTTGGAACTACATCTCTTACGGATGCTACTGCGGCTGGGGGGGCCAAGGCACGCCAAAGGACGCCA
PlaS2-cDNA AAGAAGTTGTTTCATTCTACGCCATTTACGGATGCTACTGCGGCTGGGGAGGCCAAGGCAGGGCACAGGACGCCA
PlaS1-DNA CATTTTCTGTTTGGAACTACATCTCTTACGGATGCTACTGCGGCTGGGGGGGCCAAGGCACGCCAAAGGACGCCA
PlaS2-DNA AAGAAGTTGTTTCATTCTACGCCATTTACGGATGCTACTGCGGCTGGGGAGGCCAAGGCAGGGCACAGGACGCCA
PlaS3-DNA GATTTGGTTTACTTTCTTACGTCTATTACGGATGCTACTGCGGCTGGGGAGGCCAAGGCAGGGCACAGGACGCCA

PlaS1-cDNA CCGACCG-----
PlaS2-cDNA CCGACCG-----
PlaS1-DNA CCGACCGTAAGCCTGTAACGCCCAATGACCAGAATGTGGAAGCCCTCCCGCAGGGCCGTGAGGAAGACTTCTTTC
PlaS2-DNA CCGACCGTAAGCCCGTAACCCCAATGAGCAGAAAAGTGAAGCCC-CCAGCAGGGCCATGAGGAAGACTTTCAGG
PlaS3-DNA CCGACCGTAAGCCCGTAACCCCAATGAGCAGAAAAGTGAAGCCC-CCAGCAGGGCCATGAGGAAGACTTTCAGG

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA CCTTTGGTGGGGAGGAGGAGGCTAAAATAAATTTCAGACTTGGCAAT-----TGTTTATGACGGTTCACAGTG
PlaS2-DNA -----GGTGGGGA-----ATAAATTTCAGACTTGGCAACTGGGCTCATGTTTATGACAGTTCACAGTG
PlaS3-DNA -----GGTGGGGA-----ATAAATTTCAGACTTGGCAACTGGGCTCATGTTTATGACAGTTCACAGTG

```

**Figure 34 Comparison between cDNA (*PlaS1*, *PlaS2*) and gDNA (*gPlaS1*, *gPlaS2* and *gPlaS3*). Bold letters indicated start and stop codons. The underlined is a signal sequence.**

```

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA TCCCGGGCTCCCGTGATGCCCTTT - GCGACCTCTGGATAAGCAAAATCAAGGGGAAGAAGCCAAATTCCTTC
PlaS2-DNA TCCTGGGTTCCTGTGATCCCCCTTTTGGACCTCTGGATAAAACAAAATCAAGGGG - AAGAAGCCGGATTCCCTTC
PlaS3-DNA TCCTGGGTTCCTGTGATCCCCCTTTTGGACCTCTGGATAAAACAAAATCAAGGGG - AAGAAGCCGGATTCCCTTC

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA AGAACTGCTAAGTTAAGAAATGAAGTGGGTACAAAGGTATAAAAAGGGGGCAAACTCACTTAACGACTGTCTT
PlaS2-DNA AGAACTGCTAAGTTAAGAAACGCAGTGGGTAGAAAGATCATAAAAAGGGGGCAAACTCACCTAACCACTGTCTT
PlaS3-DNA AGAACTGCTAAGTTAAGAAACGCAGTGGGTAGAAAGATCATAAAAAGGGGGCAAACTCACCTAACCACTGTCTT

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA GCTCAGCAATGGGCTCAATTGTGGCTGTAAAGGCAGAACCATCTGTAGGTGGAAGAGTCCCTTCCTCTGCCCCA
PlaS2-DNA GCTCAGCAATGGGCTCAATTGTGGCTGGAAGGCAGGACCATCTGTCCATGGAAGAGTCCCTTCCTCTGTGCCA
PlaS3-DNA GCTCAGCAATGGGCTCAATTGTGGCTGGAAGGCAGGACCATCTGTCCATGGAAGAGTCCCTTCCTCTGTGCCA

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA GACTAGCTCCCATCGTCTCAGTCGACATCAAGGATTTGTCACATCTCCAGATATGGAAAGGAACCAACTGGA
PlaS2-DNA GAATAGCTCCCATCGTCTCAGTCGCCATCCAGAATTTGACACATCTCCAGATGTTGAAAGGAACCAACTGGA
PlaS3-DNA GAATAGCTCCCATCGTCTCAGTCGCCATCCAGAATTTGACACATCTCCAGATGTTGAAAGGAACCAACTGGA

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA GAAGGGAGACACACAAAGACACACACACACACACACACACACACACACACACACACACACACAGAACATTTTG
PlaS2-DNA GGAGG-----CACACTCATAACACAAACACAG-----CAAAAACACAAACAGACCGTTTTTG
PlaS3-DNA GGAGG-----CACACTCATAACACAAACACAG-----CAAAAACACAAACAGACCGTTTTTG

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA CTTCTGCAAAATATCCCCATTGTAATGATTTACACCGGTTTTTGGGACCTGGGAGCCTCTCTGCACAATCGAT
PlaS2-DNA CCTCTGCCAAATATCCCCATTGCAATGATTTACACAGGTTCTTGGGACCGGGGAGCCTCTCTGCACGACCGAT
PlaS3-DNA CCTCTGCCAAATATCCCCATTGCAATGATTTACACAGGTTCTTGGGACCGGGGAGCCTCTCTGCACGACCGAT

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA GGGGACCCCAATCCTTTTCCAATCTTGGGTGCCAGCACCTCACCCCCACTGCTGGACAGGGACCTCTTTTCGGC
PlaS2-DNA GGGGACCCCAATCCTTTTCCAACTTGGAGTGCCAGCACCTCACCCCCATAGTTGGACAGGGGCCCTCTTTTGGC
PlaS3-DNA GGGGACCCCAATCCTTTTCCAACTTGGAGTGCCAGCACCTCACCCCCATAGTTGGACAGGGGCCCTCTTTTGGC

PlaS1-cDNA -----CTGCTGCTTCGTGCAGACTGCTGTTACGGGGAGTGAAA
PlaS2-cDNA -----CTGCTGCTTTGTGCAGACTGCTGTTACGGGACAGTGAAT
PlaS1-DNA TAACTCTGTCTGTCCCTCCCTCCCTCCCTCCAGCTGCTGCTTCGTGCAGACTGCTGTTACGGGGAGTGAAA
PlaS2-DNA TAACTCTCTCCTGCCCCCTCCCTCCCTCCCTCCAGCTGCTGCTTTGTGCAGACTGCTGTTACGGGACAGTGAAT
PlaS3-DNA TAACTCTCTCCTGCCCCCTCCCTCCCTCCCTCCAGCTGCTGCTTTGTGCAGACTGCTGTTACGGGACAGTGAAT

PlaS1-cDNA GGCTGCAACCCCAAACTGGCCATCTACTCCTACAGCTTTTCCAGAGAGGGAATATCGTCTGCG-----
PlaS2-cDNA GACTGCAACCCCAAAACGGCCACCTATTCTTACAGCTTTTGGAAACGGGGATATCGTCTGCG-----
PlaS1-DNA GGCTGCAACCCCAAACTGGCCATCTACTCCTACAGCTTTTCCAGAGAGGGAATATCGTCTGCGGTGAGTGXXXXXX
PlaS2-DNA GACTGCAACCCCAAAACGGCCACCTATTCTTACAGCTTTTGGAAACGGGGATATCGTCTGCGGTGAGTGGATGCAC
PlaS3-DNA GACTGCAACCCCAAAACGGCCACCTATTCTTACAGCTTTTGGAAACGGGGATATCGTCTGCGGTGAGTGGATGCAC

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA XXXXXXXXXXXXXAATGCTTCCCGAGCCAGAACGAAGTTGGGATGATTCTTTTCATCATCTTTGGGCAGCCTGCA
PlaS2-DNA AGACCTGGGTTCAAATGCTTCCCGAGCCAGAACCAAGCTGGGGTTGATCCTTTGATCATCTTTGGGCAGCCTGCA
PlaS3-DNA AGACCTGGGTTCAAATGCTTCCCGAGCCAGAACCAAGCTGGGGTTGATCCTTTGATCATCTTTGGGCAGCCTGCA

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA GTGGCTTTATGTAAGCTGCTCCGGGATGCAAACTCCTGTCCACCAGGGGGGCCACAATCAGGATTCCTTCGCATC
PlaS2-DNA GTGGCTTCGTGTAAGCTGCTCCTGGGTGCAAAGCTCCTGTCCACCAGGGGGGCCACAATCAGGATTCCTTCGCATC
PlaS3-DNA GTGGCTTCGTGTAAGCTGCTCCTGGGTGCAAAGCTCCTGTCCACCAGGGGGGCCACAATCAGGATTCCTTCGCATC

```

**Figure 34 (continued)**

```

PlaS1-cDNA -----
PlaS2-cDNA -----
PlaS1-DNA TCGGCTGCCCTCTAGTGGCCAGGCCAGGATTTGCAGCCCTAGGCTGAGCCGTCCGAGAGGGTGGGCAGGATTAAC
PlaS2-DNA TCGGCTGCCCTCTGGTGGACAGGCCAGGATTTCCAGCCCTAGACTGAGCCGTCCGAGAGGGTGGGCAGGATTAAC
PlaS3-DNA TCGGCTGCCCTCTGGTGGACAGGCCAGGATTTCCAGCCCTAGACTGAGCCGTCCGAGAGGGTGGGCAGGATTAAC

PlaS1-cDNA -----GAAGAAACAACGGGTGCCTGAGGACCAATTTGTGAGTGCACAGGGTCGCGGCAA
PlaS2-cDNA -----GAGACAACGACCTGTGCCTGAGGACTGTTTGTGAGTGTGACAGGGCCGCGGCAA
PlaS1-DNA CAGGATTTGCTCTGCCTGCAGGAAGAAACAACGGGTGCCTGAGGACCAATTTGTGAGTGCACAGGGTCGCGGCAA
PlaS2-DNA CAGGGTTTGTCTCTGCCTGTAGGAGACAACGACCTGTGCCTGAGGACTGTTTGTGAGTGTGACAGGGCCGCGGCAA
PlaS3-DNA CAGGGTTTGTCTCTGCCTGTAGGAGACAACGACCTGTGCCTGAGGACTGTTTGTGAGTGTGACAGGGCCGCGGCAA

PlaS1-cDNA ACTGCTTTCACCAGAATAAGAATACATACAACAAAGAATATAAGTTCCTCTCATCTCTAAATGCAGGCAGAGGT
PlaS2-cDNA TCTGCCTTGGACAGAATGTGAATACATACGACAAAACTATGAGTACTACTCAATCTCTCATTGCACGGAGGAGT
PlaS1-DNA ACTGCTTTCACCAGAATAAGAATACATACAACAAAGAATATAAGTTCCTCTCATCTCTAAATGCAGGCAGAGGT
PlaS2-DNA TCTGCCTTGGACAGAATGTGAATACATACGACAAAACTATGAGTACTACTCAATCTCTCATTGCACGGAGGAGT
PlaS3-DNA TCTGCCTTGGACAGAATGTGAATACATACGACAAAACTATGAGTACTACTCAATCTCTCATTGCACGGAGGAGT


PlaS1-cDNA CAGAGCAATGCTTAAGTCTCTGCAGGACGGGAAAAACCCCTCCAATTACACAATTTGGTTGTGTTACTCTATTAT
PlaS2-cDNA CAGAGCAATGCTTAAGTCTCTGCAGGACGGGAAAAAGCCCTCCAATTACACAATTTGGTTGTGTTACTCTATTAT
PlaS1-DNA CAGAGCAATGCTTAAGTCTCTGCAGGACGGGAAAAACCCCTCCAATTACACAATTTGGTTGTGTTACTCTATTAT
PlaS2-DNA CAGAGCAATGCTTAAGTCTCTGCAGGACGGGAAAAAGCCCTCCAATTACACAATTTGGTTGTGTTACTCTATTAT
PlaS3-DNA CAGAGCAATGCTTAAGTCTCTGCAGGACGGGAAAAAGCCCTCCAATTACACAATTTGGTTGTGTTACTCTATTAT

PlaS1-cDNA TCTGAATGCAATACTGAGCAATAAACAGGTGCCAGCTCTGCACTAAA
PlaS2-cDNA TCTGAATGCAATACTGAGCAATAAACAGGTGCCAGCTCTGCACTAAA
PlaS1-DNA TCTGAATGCAATACTGAGCAATAAACAGGTGCCAGCTCTGCACTAAA
PlaS2-DNA TCTGAATGCAATACTGAGCAATAAACAGGTGCCAGCTCTGCACTAAA
PlaS3-DNA TCTGAATGCAATACTGAGCAATAAACAGGTGCCAGCTCTGCACTAAA


```

**Figure 34 (continued)**

สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย



**Figure 35** An alignment of deduced amino acid sequences of gPlaS1, gPlaS2 and gPlaS3. Identical nucleotides were highlighted. Signal peptide sequences were underlined. Arrows indicated exon separation. An alignment showed 69% (gPlaS1:gPlaS2), 70%(gPlaS1:gPlaS3) and 92%(gPlaS2:gPlaS3) amino acid sequence identity.



Sequences producing significant alignments:	Score (bits)	E Value
gi 400714 sp P31100 PA27_DABRU Phospholipase A2 RV-7 precur...	202	1e-51
gi 30142140 gb AAP13805.1  phospholipase A2-I [Vipera russe...	201	1e-51
gi 26006833 sp Q8JFG1 PA2I_VIPAP Phospholipase A2 inhibitor...	194	2e-49
gi 31790290 gb AAP58959.1  phospholipase A2-III [Vipera rus...	189	6e-48
gi 6647690 sp Q98996 PA2A_VIPPA Phospholipase A2 isozyme ac...	178	2e-44
gi 28201853 sp Q9PWR6 PA27_VIPPA Phospholipase A2 isozyme V...	175	1e-43
gi 33187136 gb AAN59990.1  ammodytin I1 [Vipera berus berus]	172	8e-43
gi 33187128 gb AAN59986.1  ammodytin I1 [Vipera aspis aspis...	172	8e-43
gi 25453141 sp Q910A1 PA2_VIPAA Phospholipase A2, ammodytin...	171	2e-42
gi 2851544 sp P04084 PA2I_VIPAE Phospholipase A2 inhibitor ...	165	1e-40
gi 2144447 pir PSVII phospholipase A2 inhibitor - western ...	165	1e-40
gi 16974940 pdb 1JLT A Chain A, Vipoxin Complex	165	1e-40

**Figure 36 Homology searching via Internet result of deduced amino acid sequence gPlaS3 by using BLAST P program.**


สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

```

          *           20           *           40           *
gPlaS3   : NLFQFGDMINKKTGRFGLLSYVY YGICYCGWGGQGRAQDATDRCCFVHDCC : 50
PLA2-I   : NLYQFGEMINQKTGNFGLLSYVY YGICYCGWGGKGPQDATDRCCFVHDCC : 50
PLA2-II  : NLFQFARLIDAKQEAFFSFFKYISY GICYCGWGGQGPQDATDRCCFVHDCC : 50
S3       : NLFQFARMIDAKQEAFFSFWKYISY GICYCGWGGQGPQDATDRCCFVHDCC : 50
gPlaS1   : NLFQFARMINGKLGAFSVWNYISY GICYCGWGGQGPQDATDRCCFVHDCC : 50
RV-4     : NLFQFARMINGKLGAFSVWNYISY GICYCGWGGQGPQDATDRCCFVHDCC : 50
S1-2     : NLFQFAEMIVKMTGKNPLS-YSDY GICYCGWGGKGPQDATDRCCFVHDCC : 49
S1-1     : NLYQFGRMIFRMTAKNPLS-YSNY GICYCGWGGKGPQDATDRCCFVHDCC : 49
P1       : SLLEFGMILEETGKLAIPSYSSY GICYCGWGGKGPQDATDRCCFVHDCC : 50
P2-1    : SLLEFGMILEETGKLAVPFYSSY GICYCGWGGKGPQDATDRCCFVHDCC : 50
P2-2    : SLLEFGMILEETGKLAVPFYSSY GICYCGWGGKGPQDATDRCCFVHDCC : 50
P3       : SLLEFGMILGETGKNPLTSYSFY GICYCGVGGKGPQDATDRCCFVHDCC : 50
gPlaS2   : NLFQFGEMILEKTGKEV VHSYAI YGICYCGWGGQGRAQDATDRCCFVHDCC : 50
RV-7     : NLFQFGEMILEKTGKEV VHSYAI YGICYCGWGGQGRAQDATDRCCFVHDCC : 50
PLA2-III : NFFQFAEMIVKMTGKEAVHSYAI YGICYCGWGGQGPQDATDRCCFVHDCC : 50
Daboiatoxi : NFFQFAEMIVKMTGKEAVHS----- : 20
          1 2F 6I   g       y ygicycgwgg g   datdrccfvhdcc

```

**Figure 37** An alignment of N-terminal amino acid sequence PLA<sub>2</sub>s. gPlaS1, gPlaS2 and gPlaS3 were deduced from DNA. PLA2-I; *D. r. siamensis* (#AY256974), PLA2-II; *D. r. siamensis* (#AY286006), PLA2-III; *D. r. siamensis* (#AY303800), RV-4; *D. r. formosensis* (#S29298), RV-7; *D. r. formosensis* (#S29299), Daboiatoxin; *D. r. siamensis*<sup>18</sup>, S1-1; *D. r. siamensis*<sup>9</sup>, S1-2; *D. r. siamensis*<sup>9</sup>, S3; *D. r. siamensis*<sup>9</sup>, P1; *D. r. pulchella*<sup>9</sup>, P2-1; *D. r. pulchella*<sup>9</sup>, P2-2; *D. r. pulchella*<sup>9</sup>, P3; *D. r. pulchella*<sup>9</sup>.



**Figure 38 Comparison between cDNA and gDNA of PLA<sub>2</sub>s.**

สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## CHAPTER V

### CONCLUSION AND DISCUSSION

The objective of this study is to screen  $PLA_2$  isoforms of Thai Russell's viper venom and *in vivo* express of revealed  $PLA_2$ . The  $PLA_2$  expression is performed in *E. coli* and its enzymatic activity is determined. The previous reports<sup>9,18,19,22</sup> suggested that several  $PLA_2$  isoforms are found in Russell's viper venom subspecies. However, there is little information both  $PLA_2$  isoforms of Thai Russell's viper venom and their nucleotide/amino acid sequences.

#### **1. Two Types of $PLA_2$ Account for Most of the Expressed $PLA_2$ in Thai Russell's Viper**

We used 2 methods to clone  $PLA_2$  cDNA. The first is by plaque-lift DNA hybridization from cDNA library using *RVV012* probe. The second is by random sequencing for  $PLA_2$  of cDNA library obtained from ESTs study. In total of 26 clones, we found only 2 forms of  $PLA_2$  that designated *PlaS1* and *PlaS2*. The ratio of *PlaS1* and *PlaS2* cDNA found in the venom is 8:18.

Previously, Russell's viper  $PLA_2$  studies relied on  $PLA_2$  proteins, which were isolated and purified directly from snake venom by column chromatography technique. Most of  $PLA_2$  protein sequences were reported as their short N-terminal sequences usually less than 50 amino acid residues<sup>9,18</sup>. Therefore, limited data of nucleotide sequences and full-length protein sequences of  $PLA_2$  is hinder in identification and characterization clones of interest. The nucleotide sequences of Taiwan Russell's viper were available for comparison. We found that Thai Russell's viper *PlaS1* is identical to Taiwan Russell's viper  $PLA_2$ , *RV-4*, and *PlaS2* is identical to

*RV-7*. Although Thai Russell's viper (*D. r. siamensis*) and Taiwan Russell's viper (*D. r. formosensis*) are classified in different subspecies, the identical in PLA<sub>2</sub> gene sequence suggest they have closely relationship. In contrast, Daboia toxin purified from Myanmar Russell's viper (*D. r. siamensis*) show less homology to Thai Russell's viper PLA<sub>2</sub>. Thus, classification of snake subspecies by using different in coloration and marking may insufficient.

Despite 2 PLA<sub>2</sub> isoforms were found in cDNA library, the previous study which isolation PLA<sub>2</sub> from whole venom<sup>9</sup> showed that at least 5 isoforms of PLA<sub>2</sub> were found in *D. r. siamensis*. However, the isoforms classification from previous report discriminated by using only short N-terminal amino acid sequences of isolated PLA<sub>2</sub>. The absent of other PLA<sub>2</sub> isoforms probably causes by relative low amount of their mRNA compare to *PlaS1* and *PlaS2* or using snake from different geographic region.

The genomic PLA<sub>2</sub> gene organization is also one of interested. There are no full-length genomic PLA<sub>2</sub> of *Daboia russellii* spp. reported to date. We found 3 forms of PLA<sub>2</sub> gene, which designated *gPlaS1*, *gPlaS2* and *gPlaS3*. Sequence analysis of *gPlaS1* and *gPlaS2* are shown that their encode for *PlaS1* and *PlaS2* cDNA, respectively. Interestingly, *gPlaS3* was resemble to *gPlaS2* (98% nucleotide sequence identity). The isoelectric point (pI) prediction of deduced amino acid *gPlaS1*, *gPlaS2* and *gPlaS3* by using Compute pI/Mw Tool<sup>43</sup>, is 8.96, 4.46, and 4.56, respectively. The prediction result indicated that *gPlaS1* is a basic PLA<sub>2</sub> protein, while *gPlaS2* and *PlaS3* are acidic PLA<sub>2</sub> proteins. Surprisingly, an alignment of N-terminal amino acid sequences indicated that deduced amino acid sequences of *gPlaS3* is different from previous reported *D. russellii* PLA<sub>2</sub>s suggest that it is a new isoform reported to date. Therefore, this is the first report of genomic DNA sequences of *D. russellii* PLA<sub>2</sub>. However, we can not clone cDNA of *gPlaS3* from cDNA library. Probably, cDNA of

*gPlaS3* may express at very low level compare to *PlaS1* and *PlaS2*. Because predicted protein encoded from *gPlaS3* is not identical to any reported snake venom PLA<sub>2</sub>, it is possible that *gPlaS3* may express in another tissue rather than venom gland.

The *gPlaS1*, *gPlaS2* and *gPlaS3* DNAs are about 2.0 kb in length. These PLA<sub>2</sub>s gene compose of 5 exons and 4 introns similar to previously reported Viper *gPLA<sub>2</sub>*<sup>41,44,45,46</sup> such as *Vipera ammodytes ammodytin II* (accession number AF253048) which are 2142 bp and 5 exons. The initiation codon (ATG) of all 3 forms of *gPLA<sub>2</sub>* is located in exon 2 and the termination codon is located in exon 5. The signal peptides of these genes are 100% identical indicate the conservation of this region. All introns in these genes start by GT and end with AG as found in any eukaryotes. All the disulfide bridges, the active-site residues (His48, Asp49, Tyr52, Tys73 and Asp99) and the calcium-binding site (25-33, 49) of PLA<sub>2</sub> family<sup>22,47,48</sup> are all conserved (**Figure 39**).

สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย



## 2. Expression of Recombinant Russell's Viper PLA<sub>2</sub>

The successful expression of fully active recombinant PLA<sub>2</sub> of *Agkistrodon halys* Pallas in *E. coli* was reported<sup>51</sup>. High level of recombinant RVV-X expression by using vector pTrcHisA in *E. coli* was also obtained in our lab. Hence, we try to produce recombinant PlaS1 and PlaS2 in the *E. coli* using the expression vector pTrcHisA.

To optimize the expression level, IPTG concentration, incubation time after adding IPTG, and bacterial host strain were compared. As the result, 1 mM of IPTG, overnight incubation, and TOP10 host strain were selected. However, low production of PLA<sub>2</sub> was still observed (2.0 ug protein/Litre of cell culture). Generally, the average recombinant protein expression using pTrcHisA vector in *E. coli* was about 6-7 mg protein/Litre of cell culture<sup>52</sup>.

Because of a low level of PLA<sub>2</sub> expression, SDS-PAGE analysis following IPTG induction did not discriminate PLA<sub>2</sub> band between with and without IPTG induction. The Western blot analysis revealed the expected band of about 18 kDa of recombinant PlaS1. However, the expected band of recombinant PlaS2 was also 18 kDa but the 23 kDa band was obtained instead. The shifted band of recombinant PlaS2 may be caused by the unused of stop codon in its sequence. Nevertheless, amino acid prediction of PlaS2 after stop codon revealed many stop codons in all 3 frames and none of them give an expected 23 kDa protein. Moreover, recombinant PlaS2 protein also showed the lower expression level than PlaS1.

The low level of recombinant PLA<sub>2</sub> expression is probably due to mRNA secondary structure<sup>38</sup>. In previous report of PLA<sub>2</sub> expression, a double mutant ammodytoxin A was expressed in *E. coli* at a low level not exceeding 0.5% of total cell proteins<sup>38</sup>. They also found that ammodytoxin A mRNA form strong secondary

structure using RNA secondary structure prediction program. Consequently, after the replacement of strong bases that involved hindering effective translation at the ribosome with weaker bases, the new mutant was successfully produced at a level of 15% of total proteins<sup>38</sup>. Thus, we try to produce recombinant PlaS1 and PlaS2 by using Rapid Translation System (RTS) which is *In vitro* protein synthesis system based on *E.coli* lysate. The silent mutational variants calculation of our DNA with ProteoExpert RTS *E. coli* HY Program was used to avoid the effect of mRNA secondary structure on the level of expression. However, recombinant PLA<sub>2</sub> was not expressed in this system while recombinant GFP control was detected.

The other reasons that may cause the low level of PLA<sub>2</sub> expression are the low stability of PLA<sub>2</sub> mRNA or PLA<sub>2</sub> protein itself. Depletion of 5' UTR or signal peptide may cause instability of mRNA or PLA<sub>2</sub> protein as described elsewhere<sup>41</sup>. Moreover, expression as inclusion body in cells consequently loss of protein after solubilisation and refolding steps. An alternative strategy of soluble protein production is to direct the protein to the periplasm of *E.coli* cells, where disulfide bridges are spontaneously formed, by using signal peptide tag such as maltose-binding protein<sup>53</sup>.

### 3. PLA<sub>2</sub> Activity

PLA<sub>2</sub> is tested for their *in vitro* enzymatic activity by using spectrophotometric method<sup>39</sup>. This method is easy and rapid. The result showed that recombinant PlaS1 had enzymatic activity of 185.67 μmoles/min/mg. We attempted to use the chromatographic fraction containing PLA<sub>2</sub> proteins separated from Russell's viper crude venom as a control in activity assay. However, after incubation of control with its substrate, the mixture was precipitated in a few minutes. Although the enzymatic activity of PLA<sub>2</sub> control could not be assessed, the mixture reaction shown

the changing in color after enzyme adding, indicating that it possesses enzymatic activity.

There was a paper reported that the enzymatic activity of PLA<sub>2</sub> is not correlate with their LD<sub>50</sub><sup>36</sup>. However, the amount of recombinant pLA<sub>2</sub> was not enough to assess the biological role of PLA<sub>2</sub> that was previously planned, for example platelet aggregation inhibition and LD<sub>50</sub>.



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## REFERENCES

1. Barry, S.G; Richard, C.D. and Robert, A.B. Bites of venomous snakes. **N Engl J Med** 2002; 347(5) : 347-356.
2. ไพบุลย์ จินตกุล และ ลาวัณย์ จันทร์โฮม. **งูพิษในประเทศไทย**. พิมพ์ครั้งที่ 1. กรุงเทพมหานคร : สถาบันเสาวภา สภากาชาดไทย, 2539.
3. Warrell, D. A. Snake venoms in science and clinical medicine-1. Russell's viper: biology, venom and treatment of bites. **Trans R Soc Trop Med Hyg** 1989; 83 : 732-740.
4. ชาญ โปชนุกูล. งูพิษกัดในประเทศไทย, ใน **พิษจากพืช สัตว์ และจุลชีพ**, หน้า 1-33. กรุงเทพมหานคร : จุฬาลงกรณ์มหาวิทยาลัย, 2531.
5. วิโรจน์ นุตพันธุ์, นาวาอากาศโท. งูพิษ. ใน **การรักษาผู้ป่วยถูกงูพิษกัดและงูพิษ**, หน้า 1-25. กรุงเทพมหานคร : ศูนย์สัตวศาสตร์ไทย, 2525.
6. Phillips, R.E., et al. Paralysis, rhabdomyolysis and haemolysis caused by bites of Russell's viper (*Vipera russelli pulchella*) in Sri Lanka: failure of Indian (Haffkine) antivenom. **Q J Med** 1988; 68 : 691-716.
7. Than-Than, et al. Heamostatic disturbances in patients bitten by Russell's viper (*vipera russelli siamensis*) in Burma. **Br J Haematol** 1988; 69 : 513-520.
8. Matsui, T.; Fufimura, Y. and Titani, K. Snake venom proteases affecting hemostasis and thrombosis. **Biochimica et Biophysica Acta** 2000; 1477 : 146-156.
9. Tsai, I. H.; Lu, P. J. and Su, J. C. Two types of Russell's viper revealed by variation in phospholipase A<sub>2</sub> from venom of the subspecies. **Toxicon** 1996; 34(1) : 99-109.
10. Kini, R. M. and Iwanaga, S. Structure-function relationships of phospholipases I: Prediction of presynaptic neurotoxicity. **Toxicon** 1986; 24 : 527.
11. Kini, R. M. Phospholipase A<sub>2</sub>- a complex multifunctional protein puzzle. In R. M. Kini (ed), **Venom phospholipase A<sub>2</sub> enzymes: structure, function and**

- mechanism**, pp.1-28. England : John Willey & Sons, 1997.
12. Dennis, E. A. Diversity of group types, regulation, and function of phospholipase A<sub>2</sub>. **J Biol Chem** 1994; 269 :13057-13060.
  13. Dennis, E.A. The growing phospholipase A<sub>2</sub> superfamily of signal transduction enzymes. **Trends Biochem Sci** 1997; 22 : 1-2.
  14. Sundell, I.B., et al. The inhibition of platelet aggregation and blood coagulation by *Micropechis ikaheka* venom. **Br J Haematol** 2001; 114(4) : 852-860.
  15. Stefansson, S; Kini, R.M. and Evans, H.j. The inhibition of clotting complexes of the extrinsic coagulation cascade by the phospholipase A<sub>2</sub> isoenzymes from *Naja nigricollis* venom. **Thromb Res** 1989; 55(4) : 481-491.
  16. Kole, L.; Chakrabarty, D.; Datta, K. and Bhattacharyya, D. Purification and characterization of an organ specific haemorrhagic toxin from *Vipera russelli russelli* (Russell's viper) venom. **Indian J Biochem Biophys** 2000; 37(2) : 114-120.
  17. Chakrabarty, D; Datta, K.; Gomes, A and Bhattacharyya, D. Haemorrhagic protein of Russell's viper venom with fibrinolytic and esterolytic activities. **Toxicon** 2000; 38(11) : 1475-1490.
  18. Maung-Maung-Thwin; Gopalakrishnakone, P.; Yuen, R. and Tan, C. H. A major lethal factor of the venom of Burmese Russell's viper (*Daboia russelli siamensis*): isolation, N-terminal sequencing and biological activities of daboiatoxin. **Toxicon** 1995; 33(1) : 63-76.
  19. Prasad, B. N.; Kemparaju, K.; Bhatt, K. G. and Gowda, T. V. A platelet aggregation inhibitor phospholipase A<sub>2</sub> from Russell's viper (*Vipera russelli*) venom : isolation and characterization. **Toxicon** 1996; 34(10) :1173-1185.
  20. Vishwanath, B. S.; Kini, R. M. and Gowda, T. V. Purification and partial biochemical characterization of an edema inducing phospholipase A<sub>2</sub> from *Vipera russelli* (Russell's viper) snake venom. **Toxicon** 1988; 26(8) : 713-720.

21. Kasturi, S. and Gowda, T. V. Purification and characterization of a major phospholipase A<sub>2</sub> from Russell's viper (*Vipera russelli*) venom. **Toxicon** 1989; 27(2) : 229-237.
22. Wang, Y. M.; Lu, P. J.; Ho, C. L. and Tsai, I. H. Characterization and molecular cloning of neurotoxic phospholipase A<sub>2</sub> from Taiwan viper (*Vipera russelli formosensis*). **Eur J Biochem** 1992; 209(2) : 635-641.
23. Balsinde, J.; Balboa, M. A.; Insel, P. A. and Dennis, E. A. Regulation and inhibition of phospholipase A<sub>2</sub>. **Annu Rev Pharmacol Toxicol** 1999; 39 : 175-189.
24. Snyder, F. Platelet-activating factor: the biosynthetic and catabolic enzymes. **Biochem J** 1995; 305 : 689-705.
25. Prasad, B. N.; Uma, B.; Bhatt, K. S. and Gowda, T. V. Comparative characterization of Russell's viper (*Daboia/vipera russelli*) venoms from different regions of the Indian peninsula. **Biochimica et Biophysica Acta** 1999; 1428(2-3) :121-136.
26. Daltry, J.C.; Wuster, W. and Thorpe, R.S. Diet and snake venom evolution. **Nature** 1996; 379 : 537-540.
27. Calderon, L. and Lomonte, B. Immunochemical characterization and role in toxic activities of region 115-129 of myotoxin II, a Lys49 phospholipase A<sub>2</sub> from *Bothrops asper* snake venom. **Arch Biochem Biophys** 1998; 358(2) : 343-50.
28. Kemparaju, K.; Krishnakanth, T. P. and Gowda, T. V. Purification and characterization of a platelet aggregation inhibitor acidic phospholipase A<sub>2</sub> from Indian saw-scaled viper (*Echis carinatus*) venom. **Toxicon** 1999; 37(12) :1659-71.
29. Singh, G.; Gourinath, S.; Sharma, S.; Paramasivam, M.; Srinivasan, A. and Singh, T. P. Sequence and crystal structure determination of a basic phospholipase A<sub>2</sub> from common krait (*Bungarus caeruleus*) at 2.4Å resolution : identification and characterization of its pharmacological sites. **J Mol Biol** 2001; 307(4) :1049-

- 59.
30. Mancheva, I.; Kleinschmidt, T.; Aleksiev, B. and Braunitzer, G. **Sequence homology between phospholipase and its inhibitor in snake venom. The primary structure of the inhibitor of vipoxin from the venom of the Bulgarian viper (*Vipera ammodytes ammodytes*, Serpentes). *Hoppe Seylers Z Physiol Chem* 1984; 365(8) : 885-94.**
31. Mancheva, I.; Kleinschmidt, T.; Aleksiev, B and Braunitzer, G. Sequence homology between phospholipase and its inhibitor in snake venom. The primary structure of phospholipase A<sub>2</sub> of vipoxin from the venom of the Bulgarian viper (*Vipera ammodytes ammodytes*, Serpentes). ***Biol Chem Hoppe Seyler* 1987; 368(4) : 343-52.**
32. Krizaj, I; Liang, N.S.; Pungercar, J.; Strukelj, B.; Ritonja, A. and Gubensek, F. Amino acid and cDNA sequences of a neutral phospholipase A<sub>2</sub> from the long-nosed viper (*Vipera ammodytes ammodytes*) venom. ***Eur J Biochem* 1992; 204(3) : 1057-62.**
33. Ritonja, A. and Gubensek, F. **Ammodytoxin A, a highly lethal phospholipase A<sub>2</sub> from *Vipera ammodytes ammodytes* venom. *Biochim Biophys Acta* 1985; 828(3) : 306-312.**
34. Ritonja, A.; Machleidt, W.; Turk, V. and Gubensek, F. **Amino-acid sequence of ammodytoxin B partially reveals the location of the site of toxicity of ammodytoxin. *Biol Chem Hoppe Seyler* 1986; 367(9) : 919-923.**
35. Krizaj, I.; Turk, D.; Ritonja, A. and Gubensek, F. **Primary structure of ammodytoxin C further reveals the toxic site of ammodytoxin. *Biochim Biophys Acta* 1989; 999(2) : 198-202.**
36. Rosenberg, P. Lethal potency of snake venom phospholipase A<sub>2</sub> enzymes. In R. M. Kini (ed), **Venom phospholipase A<sub>2</sub> enzymes: structure, function and mechanism**, pp.129-150. England : John Willey & Sons, 1997.

37. Fletcher, J.E.; Rapuano, B.E.; Condrea, E.; Yang, C.C. and Rosenberg, P. **Relationship between catalysis and toxicological properties of three phospholipases A<sub>2</sub> from elapid snake venoms.** *Toxicol Appl Pharmacol* 1981; 59(2) : 375-388.
38. Yates, S.L. and Rosenberg, P. **Comparative effects of phospholipase A<sub>2</sub> neurotoxins and enzymes on membrane potential and Na<sup>+</sup>/K<sup>+</sup> ATPase activity in rat brain synaptosomes.** *Toxicol Appl Pharmacol* 1991; 109(2) : 207-218.
39. Araujo, A. L. and Radvanyi, F. Determination of phospholipase A<sub>2</sub> activity by a colorimetric assay using a pH indicator. *Toxicon* 1987; 25 : 1181-1188.
40. Nuchprayoon, I., et al. Molecular cloning of phospholipase A<sub>2</sub> from a Thai Russell's viper venom gland cDNA library. *J Med Assoc Thai* 2001; 84(Suppl1) : s99-s105.
41. Danse, J.M.; Gasparini, S. and Menez, A. Molecular biology of snake venom phospholipase A<sub>2</sub>. In R.M. Kini (ed), **Venom phospholipase A<sub>2</sub> enzymes: structure, function and mechanism**, pp.29-64. England : John Willey & Sons, 1997.
42. Georgiou, G. Expression of proteins in bacteria. In J.L. Cleland and C.S. Craik (ed), **Protein engineering**, pp.101-128. Canada : Wiley-Liss, 1996.
43. Appel, R.D.; Bairoch, A. and Hochstrasser, D.F. **Compute pI/Mw Tool** [Online]. 1993. Available from: [http://kr.expasy.org/tools/pi\\_tool.html](http://kr.expasy.org/tools/pi_tool.html) [2003, September 15]
44. Gubensek, F. and Kordis, D. Venom phospholipase A<sub>2</sub> genes and their molecular evolution. In R. M. Kini (ed), **Venom phospholipase A<sub>2</sub> enzymes: structure, function and mechanism**, pp.73-96. England : John Willey & Sons, 1997.
45. Kramer, R.M., et al. **Structure and properties of a human non-pancreatic phospholipase A<sub>2</sub>.** *J Biol Chem* 1989; 264 : 5768 - 5775.
46. Seilhamer, J.J., et al. **Cloning and recombinant expression of phospholipase A<sub>2</sub>**

- present in rheumatoid arthritic synovial fluid. J Biol Chem** 1989; 264 : 5335 - 5338.
47. White, S.P.; Scott, D.L.; Otwinowski, Z.; Gelb, M.H. and Sigler, P.B. **Crystal structure of cobra-venom phospholipase A<sub>2</sub> in a complex with a transition-state analogue. Science** 1990; 250(4987) : 1560-1563.
48. Scott, D.L. Phospholipase A<sub>2</sub>: structure and catalytic properties. In R. M. Kini (ed), **Venom phospholipase A<sub>2</sub> enzymes: structure, function and mechanism**, pp.97-128. England : John Willey & Sons, 1997.
49. Gowda, V.T.; Schmidt, J. and Middlebrook, J.L. Primary sequence determination of the most basic myonecrotic phospholipase A<sub>2</sub> from the venom of *Vipera russelli*. **Toxicon** 1994; 32(6) : 665-673.
50. Scott, D.L. and Sigler, P.B. **Structure and catalytic mechanism of secretory phospholipases A<sub>2</sub>. Adv Protein Chem** 1994; 45 : 53-88.
51. Zhong, X.; Liu, J.; Wu, X. and Zhou, Y. Expression, purification and biochemical characterization of a recombinant phospholipase A<sub>2</sub>, with anticoagulant activity from *Agkistrodon halys* Pallas. **J Nat Toxins** 2001; 10(1) : 17-25.
52. Saulnier-Blache, J.S.; Girard, A.; Simon, M.F.; Lafontan, M. and Valet, P. A simple and highly sensitive radioenzymatic assay for lysophosphatidic acid quantification. **J Lipid Res** 2000; 41(12) : 1947-1951.
53. Giuliani, C.D. et al. Expression of an active recombinant lysine 49 phospholipase A<sub>2</sub> myotoxin as a fusion protein in bacteria. **Toxicon** 2001; 39 : 1595-1600.



# APPENDIX

สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## APPENDIX

### CHEMICAL AGENTS AND INSTRUMENTS

#### A. Research Instruments

Automatic adjustable micropipette (Eppendorf, Germany)

Balance (Precisa, Switzerland)

Beaker (Pyrex)

Combs (BIO-RAD, USA)

Chromatography and fraction collection system (BioLogig LP™ System from BIO-RAD, USA)

DNA Thermal cycler 2400 (Perkin Elmer, Cetus USA)

Electrophoresis Chamber set (BIO-RAD, USA)

Flask (Pyrex)

Chemi Doc (BIO-RAD, USA)

Glass Pipette (Witeg, Germany)

Heat block (Bockel)

Parafilm (American National Can, USA)

Pipette boy (Tecnomara, Switzerland)

Pipette rack (Autopack, USA)

Pipette tip (Axygen, USA)

Plastic wrap

Polypropylene conical tube (Elkay, USA)

Power supply model

pH meter (Eutech Cybernataics)

Microcentrifuge (Eppendorf, USA)

Microcentrifuge tube (BIO-RAD, Elkay, USA)

Reagent bottle (Duran)

Spectrophotometer (BIO-RAD, USA)

Thermometer (Precision, Germany)

Vortex (scientific Industry, USA)

Water bath

## **B. General Reagents**

Absolute ethanol (Merck)

Acetic acid (Merck)

Acrylamide:Bisarylamide (Phamacia Amersham)

Agar (Scharlau)

Agarose (USB)

Ammonium persulphate (Phamacia Amersham)

Ampicillin (M&H manufacturing)

Bromophenol blue (USB)

Calcium chloride (Merck)

Chloroform (Merck)

EDTA (Merck)

Ethidium bromide (Sigma)

Guanidine (USB)

Glucose (Merck)

Glycerol (Phamacia Amersham)

Glycine (USB)

Hydrochloric acid (Merck)

Hydrogen peroxide (Sigma)

IPTG (USB)

Isoamyl alcohol (Merck)

Maltose (Sigma)

Magnesium chloride (Fluka)

Magnesium sulphate (Sigma)

2-Mercaptoethanol (Pharmacia Amersham)

MES (USB)

Methanol (Merck)

Nickel chloride (Sigma)

NZY (Gibco)

Phenol (Sigma)

Phenol red (Sigma)

Potassium acetate (BDH)

Proteinase K (Pharmacia Amersham)

RNase A

Sodium acetate (Merck)

Sodium chloride (Scharlau)

Sodium citrate (Sigma)

SDS (Sigma)

Sodium dihydrogenphosphate (Fisher Scientific)

Sodium hydroxide (Merck)

Sucrose (Sigma)

TEMED (Gibco)

Tris base (USB)

Triton X-100 (Sigma)

Tryptone (Scharlau)

Urea (USB)


Yeast extract (Scharlau)

100 bp DNA ladder (Biolabs)

1 kb DNA ladder (Gibco)

**C. Buffer of enzymes**


1. *Taq* DNA Polymerase 10X buffer (50 mM KCl, 10 mM Tris-HCl (pH9.0 at 25<sup>o</sup>C), 1.5 mM MgCl<sub>2</sub> and 0.1% TritonX-100 when diluted 1:10)
2. *Pfu* DNA Polymerase 10X buffer (100 mM KCl, 200 mM Tris-HCl (pH8.8 at 25<sup>o</sup>C), 20 mM MgSO<sub>4</sub>, 100 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 1 mg/ml nuclease-free BSA and 1% TritonX-100)
3. T4 DNA Ligase 10 X buffer (660 mM Tris-HCl (pH 7.6), 66 mM MgCl<sub>2</sub>, 100 mM DTT, 660 μM ATP)



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย

## BIOGRAPHY

<b>Name</b>	Miss Sawatdirak Phongtananant	<b>Sex</b>	Female
<b>Birth date</b>	Feb18, 1978	<b>Age</b>	25
<b>Nationality</b>	Thai		
<b>Place of birth</b>	Bangkok, Thailand		
<b>Home address</b>	94 Soi 110 junction4, Ladprao Rd, Wangtonglang, Bangkok, 10310 Thailand		
<b>Education</b>	2000 : Bachelor of Science (Biology) Srinakharinwirot University		



สถาบันวิทยบริการ  
จุฬาลงกรณ์มหาวิทยาลัย